

MICHAEL R. BRISTOW, M.D., PH.D.

BIOGRAPHICAL INFORMATION

A. Identifying information

Nationality: United States citizen

Married (Karyn A.), three children (Justin, born July 16, 1983; Nathan, born February 27, 1986; Jacques, born November 29, 1991)

Address: 5 Blackmer Road, Cherry Hills Village, CO 80113

Phone: 303-315-4398 (office); 315-6386 (laboratory); 720-528-3888 (home); FAX 303-315-5082 (office), 303-315-3261 (laboratory); E-mail: Michael.Bristow@UCHSC.edu

B. Complete academic history

1. Colleges and universities attended

- a. University of Illinois, Urbana (1962–1966)
- b. University of Illinois, Chicago (College of Medicine) (1966–1970)
- c. University of Illinois, Chicago (Graduate College, MD-PhD Program, 1967–1971)

2. Degrees received, with dates

- a. B.S., Veterinary Science, University of Illinois, June 18, 1966
- b. M.D., University of Illinois, September 5, 1970 (with honors)
- c. Ph.D. (Pharmacology), University of Illinois, 1971

3. Scholarships and academic honors

- a. University of Illinois Edmund J. James Scholar, 1962–66, (awarded to students in upper 2% of entering applicants).
- b. Tom C. Reeves Memorial Outstanding Sophomore Award, University of Illinois College of Medicine, 1969, (awarded to outstanding student in sophomore class).
- c. Williamson Department of Medicine Award, University of Illinois, College of Medicine, 1970, (awarded to outstanding student in inpatient medicine clerkship).
- d. Borden award for undergraduate research, University of Illinois, 1970, (awarded for the top undergraduate research performed by a medical student).
- e. Alpha Omega Alpha, University of Illinois College of Medicine, 1970.
- f. Graduate with honors, University of Illinois, College of Medicine, 1970.
- g. The Therapeutic Frontiers Award, presented by the American College of Clinical Pharmacy, 1993, for development of β -blockade as a treatment for chronic heart failure.
- h. Citation Classic “Decreased catecholamine sensitivity and beta adrenergic receptor density in the failing human heart,,: Current Contents, November 1, 1993.
- i. Listed as one of Best Doctors in America, 1995 and thereafter.
- j. Ranked by *Science Watch* (July-August 1999) number 6 worldwide and first among heart failure investigators in impact of cardiovascular publications between 1993-1997 (10 high-impact papers, 142 citations/paper).
- j. The Ed Ricketts Award for Outstanding Contributions to Cardiovascular Medicine and Therapeutics, Monterey Chapter American Heart association, April 2000.
- k. Original Member, ISI® Highly Cited Researchers, 2002.
- l. University of Colorado Technology Transfer Life Sciences Inventor of the Year Award, 2002.
- m. Pinnacles of Inventorship Award, University of Colorado Technology Transfer Corporation, 2003.
- n. Clinical Science Award, Scientific Sessions Poster Competition, AHA annual meeting, 2005
- o. National 2005 Businessman of the Year Award, 2006; NRCC.

4. Fellowship and residency training

- | | |
|---------|---|
| 1970–71 | National Institutes of Health Postdoctoral Fellow, Department of Pharmacology, University of Illinois |
| 1971–72 | Intern, Internal Medicine, Stanford University School of Medicine |

1974–76 Research Fellow in Medicine/Oncology, Stanford University Medical Center
 1976–77 Resident, Department of Medicine, Stanford University School of Medicine
 1977–80 Fellow in Cardiology, Stanford University Medical Center

5. *Other study or research appointments*

1979 Visiting Fellow, Department of Biochemistry, Duke University (Dr. Robert Lefkowitz)
 1979–82 Young Investigator of National Heart, Lung and Blood Institute, National Institutes of Health
 1986–87 Visiting Professor, Department of Human Genetics, Howard Hughes' Genetics Institute, University of Utah (Dr. Raymond F. Gesteland)

6. *NIH or Foundation Grants awarded (P.I. or co-P.I. of PPG or consortium)*

1979–82 Young Investigator Award, National Heart, Lung and Blood Institutes of Health, "Ionized Calcium in Cardiac Disease."
 1983–88 Clinical Heart and Heart-Lung Transplantation; Program Project Grant. E. Stinson P.I. Project Leader on Section VI. "Pathophysiology and Pharmacology."
 1985–88 Clinical Heart and Heart-Lung Transplantation Grant (Supplement) Subproject, Principal Investigator: Pathophysiology and Pharmacology.
 1989–94 General Clinical Research Center Award. "β-Adrenergic Mechanisms in the Intact Failing Human Heart." Co-Principal Investigator. 3 MO1 RR00064-25S1
 1993–98 Principal Investigator on "Adrenergic Mechanisms in the Intact Failing Human Heart." RO1 HL48013.
 1993–97 Co-Principal Investigator on "Beta-blockade in Mitral Regurgitation." R01 HL38185, Principal Investigator B. Carabello (Consortium with University of South Carolina)
 1996–02 Principal Investigator on "Postgraduate Training in Cardiovascular Research." 5T32 HL07822, NIH NRSA Training Grant in Cardiology, \$955,000 in direct costs over 5 years.
 1998–03 Principal Investigator on "Contractile Protein Expression in Failing Human Heart." 1R01 HL616401; \$1,250,000 in direct costs over 5 years.
 1998–03 Principal Investigator on "Altered Gene Expression in the Failing Human Heart." 2R01 HL48013; \$2,009,431 in direct costs over 5 years.
 2002-04 Principal Investigator on "Dynamic Expression Profiling in the Human Heart." 1R01 HL71118; \$200,000 in direct costs over 2 years.
 2003-07 1HL69009; Neurohormonal Core Laboratory for the STICH Trial, \$105,000 in direct costs.
 2004-2008 Principal Investigator on "Genetic-Adrenergic Interactions in Myocardial Failure." 3R01 HL48013, 1.91 M in direct costs over 4 years.
 2006-2011 Core Leader/PI, "Localized Control of cAMP Signaling and Novel Therapeutic Approaches for Heart Failure ", Leducq Transatlantic Networks of Excellence Grant, 709,090 in direct costs over 5 years.
 2006- In Preparation: "Molecular and Structural Remodeling by CRT" (P01), M.Bristow P.I.

C. Complete employment record

Academic employment

2004-present Graduate School Faculty Member, University of Colorado HSC
 2000-present S.Gilbert Blount Professor of Medicine (Cardiology), University of Colorado School of Medicine
 1998–present Co-Director, University of Colorado Cardiovascular Institute
 1991–2004 Head, Cardiology Division, University of Colorado School of Medicine
 1991–present Professor of Medicine (Cardiology), University of Colorado School of Medicine
 1991–2004 Director, Temple Hoyne Buell Heart Center, University of Colorado Health Sciences Center
 1988–91 Professor of Internal Medicine (Cardiology), University of Utah School of Medicine
 1988–91 Associate Adjunct Professor, Department of Pharmacology and Toxicology, University of Utah

1984–88 Associate Professor of Medicine (Cardiology) University of Utah School of Medicine, Salt Lake City, Utah
 1984–88 Senior Research Associate, Department of Cardiovascular Surgery, Stanford University
 1983–84 Assistant Professor of Medicine (Cardiology), Stanford University School of Medicine, Stanford University
 1980–83 Physician Specialist, Stanford University Hospital, Stanford, California
 1977–80 Fellow in Cardiology, Stanford University Medical Center
 1976–77 Resident, Department of Medicine, Stanford University School of Medicine
 1974–76 Research Fellow in Medicine/Oncology, Stanford University Medical Center
 1972–74 National Health Corps assignee, West Yellowstone, Montana
 1971–72 Intern, Internal Medicine, Stanford University School of Medicine
 1970–71 National Institutes of Health Postdoctoral Fellow, Department of Pharmacology, University of Illinois

D. Public service

National Health Corps assignee, West Yellowstone, Montana, 1972–74 (U.S. Public Health Service)
 Established first National Health Service Field Station in Montana and for two years served as the sole medical practitioner within a 75-mile radius.

E. University Service, University of Colorado

Member, UCHSC Chancellor’s Society, FY 2005
 Member, University of Colorado Technology Transfer Committee, 2003 -
 Member, UCHSC/Fitzsimons Research Park Advisory Committee, 2002 -
 University Physicians, Inc. Clinical Practice Committee Member (1996-1999)
 School of Medicine Sites of Practice Committee Member (1992-1999)
 UCHSC Faculty Senate Committee (1997-1999)
 SOM Research Resource Development/Utilization Task Group (1996-1998)
 SOM Biotech Subcommittee of Research Resource Development Committee (1996-1998)
 Department of Medicine Faculty Development Committee (1993-1994)

F. Academic Administrative experience

1998–present Co-Director, University of Colorado Cardiovascular Institute
 1991–2004 Head, Division of Cardiology, University of Colorado School of Medicine
 1991–2004 Director, Temple Buell Hoyne Heart Center, University of Colorado Health Sciences Center
 1986–1991 Director of Research, UTAH Cardiac Transplant Program
 1985–1986 Founder and Acting Medical Director, UTAH Cardiac Transplant Program
 1984–1991 Director, University and LDS Hospitals Heart Failure Treatment Program (Transplant/Heart Failure Clinical Service + Clinics), University of Utah

G. Editorial Boards/NIH Study Sections

2001-present JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY Editorial Board
 2001-2002 Member, NHLBI Innovative Research Grant Program Study Section
 2002-present HEART FAILURE MONITOR Editorial Advisory Board
 1999-2004 J CARDIAC FAILURE Editorial Board
 1999-present INTERNATIONAL JOURNAL OF CARDIOLOGY Editorial Board
 1999-2001 JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY Ed. Brd.
 1999-present JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Ed. Brd.
 1988–1992 CIRCULATION RESEARCH Editorial Board
 1986–1996 CARDIOVASCULAR DRUGS AND THERAPY Editorial Board
 1988–present CONGESTIVE HEART FAILURE Editorial Board
 1991–present CIRCULATION Editorial Board
 1999–present CIRCULATION Consulting Editor
 1994–1997 Member, NIH Cardiovascular Study Section B
 1995-present JOURNAL OF CARDIOVASCULAR PHARMACOLOGY editorial board

H. National/International Task Forces & Committees

Member, NHLBI Special Emphasis Panel on Heart Failure
Participant, Bethesda Meeting/Task Force on Cardiac Transplantation (Donor Supply)
Member, NIH Task Force on Heart Failure (basic research)
Member, Joint ACC-AHA Task Force on Heart Failure
Member, AHA Task Force on Cardiac Transplantation
Member, International Society of Cardiology Scientific Council on Cardiomyopathies
Member, UNOS Subcommittee on Listing Criteria for Cardiac Transplantation
Member, WHO International Heart Failure Education Council
Member, NHLBI Task Force on Research in Heart Failure
Member, NIH SPARK Task Force (1998-1999)
ACC Cardiovascular Research Committee (1999-2002)
Chairman of Scientific Program Committee, Heart Failure Society of America (1999-2001)
Member, AHA Desert/Mountain Affiliate Research Committee (2001-).
Member, NHLBI Special Emphasis Review Study Section for RFA-01-016, 2002
Chairman, Protocol Review Committee, NHLBI TOPCAT Trial, 2005-
Chairman, Data and Safety Monitoring Committee, NHLBI TOPCAT Trial, 2005-
NRCC Business Advisory Council, 2006-

I. Licenses and certificates

Diplomate, American Board of Internal Medicine - 1977
Diplomate, A.B.I.M., subspecialty of cardiovascular disease - 1981
Licensed to practice medicine in California, Idaho, Montana, Utah and Colorado.

J. Societies

Member, American Heart Association
Fellow, American College of Cardiology
Member, International Society for Heart Transplantation
Member, American Society for Clinical Investigation (1985–)
Member, American Federation for Clinical Research
Invited Member (Corresponding Member), British Cardiac Society
Member, American Society of Transplant Physicians
Member, Association of University Cardiologists (1992–)
Member, Association of American Physicians (1994–)
Founding Member, American Heart Failure Society (1995–)

K. Ph.D.s Trained

Jonathan David Port, Ph.D. (1985-1989) Beta-adrenergic Receptor Model Systems
Current position: Associate Professor, Division of Cardiology and Pharmacology, University of Colorado School of Medicine
Ronald Zolty, MD (2003-2007) Adrenergic Receptor Polymorphisms
Current Position: Assistant Professor of Medicine (Cardiology), University of Colorado School of Medicine
Brian Lowes, MD (2004-2007) Expression Profiling in the Intact Human Heart
Current Position: Associate Professor of Medicine (Cardiology), University of Colorado School of Medicine

L. Post-Doctoral Fellows trained in basic or clinical research and current position

Michael Fowler, M.D. (1981-1983). Associate Professor of Medicine (Cardiology), Stanford University, Stanford, CA.
E. Michael Gilbert, M.D. (1985–1988). Professor of Medicine (Cardiology), University of Utah School of Medicine.
Ray E. Hershberger, M.D. (1986–1990). Associate Professor (Cardiology), University of Oregon, Department of Medicine

- Michel White, M.D. (1990–1993). Beta Receptor Changes with Aging. Assistant Professor of Medicine (Cardiology), University of Montreal, Montreal Heart Institute.
- William T. Abraham, M.D. (1991–1993). Natriuretic Peptides in CHF. Professor of Medicine and Chief (Cardiology), The Ohio State University.
- Lawrence S. Zisman, M.D. (1993–1996) ACE gene expression in failing human heart. Associate Professor of Medicine, Albany Medical College, Albany, NY.
- Brian T. Lowes, M.D. (1992-1996) In Vivo gene expression measurements in human heart. Associate Professor of Medicine (Cardiology) University of Colorado Health sciences Center.
- Simon Shakar, M.D. (1994-1998) PDEI – beta blocker combination in CHF. Assistant Professor of Medicine (Cardiology) University of Colorado Health sciences Center.
- Magdy Tawadrous, M.D. (1997-2000) Alpha-MYHC gene regulation. Post-dosctoral fellow, NYU Division of Cardiology
- Koji Asano, M.D. (1996-2000) Angiotensin II receptors in failing heart. Instructor, First Department of Physiology, Yamagata University School of Medicine, Yamagata City Japan, (1997-2001)
- Koichiro Kinugawa, M.D. (1999-2002) Thyroid hormone receptor dysregulation in failing heart.
- Jennifer V. Linseman, Ph.D. (2001-2003) Contractile Protein Expression in Failing Human Heart. Myogen, Inc., Westminster, CO.
- Carmen Sucharov, Ph.D. (2002-present) Cardiac hypertrophy/failure. Assistant Professor, Division of Cardiology, University of Colorado Health Sciences Center.
- DeAnn Rivera, M.D. (2003-present) Evaluation of Reverse Modeling in Cardiac Resynchronization Therapy. Fellow, Division of Cardiology, University of Colorado Health Sciences Center.
- Peter Robinson, M.D. (2004-present) Effect of alterations in PPAR- α on myocardial hypertrophy and fetal gene induction. Fellow, Division of Cardiology, University of Colorado Health Sciences Center.

M. Business/Entrepreneurial Experience

1982. Co-Founder, CPEC, Inc, San Francisco, CA (sold to Interneuron, Inc in 1994).
1996. Founder and Scientific Co-founder, Myogen, Inc, Westminster, CO; traded on NASDAQ beginning 10/30/03 (MYOG).
- 1998-present Director, Myogen Inc Westminster, CO.
- 1998-present Chief Scientific and Medical Officer, Myogen, Inc, Westminster, CO
2001. Founder and Scientific Co-Founder, ARCA Discovery, Inc, Aurora, CO.
- 2001-present Director, ARCA Discovery, Inc, Aurora, CO.
- 2001-present President and CEO, ARCA Discovery, Aurora, CO
- 2000-present On Scientific Advisory Boards of Myogen (Chairman), Cardiovascular Clinical Research (C₂R), Genzyme, Covalent, CVRx, Myomatrix, Cardiac Dimensions, Inspiration Medical.

N. Patents

1. “Method of treating heart failure.” Michael R. Bristow. U.S. Patent 5,998,458 issued 6/30/99. This patent is for the use of positive inotropic agents and β -blockers as a combined treatment of heart failure. European patent pending
2. “Transgenic Model and Treatment for Heart Disease” J. David Port and Michael R. Bristow. U.S. Patent 6,218,597 issued 4-17-01. Transgenic mouse model over-expressing the human β_1 -adrenergic receptor, with claims for use as a screening tool for new heart failure therapeutic agents and for exploring the molecular basis of heart failure.
3. “Method for Identifying Adrenergic Receptor Antagonists Having Good Tolerability.” Michael R. Bristow and J. David Port. U.S. Patent 6,203,776 issued 3-20-01. For the use of a transgenic model in identifying β -adrenergic receptor ligands with improved therapeutic properties.

4. "Diagnosis and treatment of myocardial failure." Michael R. Bristow, Leslie A. Leinwand, Wayne Minobe, Koichi Nakao. U.S. Patent 7,049,066 5/23/06. For the use of myosin heavy chain isoform changes as diagnostic and therapeutic tools in human heart failure.
5. "Expression Profiling in the Intact Human Heart." Michael R. Bristow, Wayne Minobe, Brian Lowes, M. Benjamin Perryman. U.S. Patent application 10/241,368; Canada application No. 2,460,117 a) For the use of microarray expression profiling conducted serially in an intact organ, with sampling done before and after effecting a phenotypic change, and b) For the discovery of specific novel genes involved in the improvement in the dilated cardiomyopathy phenotype.
6. "Inhibition of histone deacetylase as a treatment for cardiac hypertrophy" Carlin Long, Eric Olson, Tim McKinsey, Michael R. Bristow. Provisional application filed 10-31-01, converted 9/26/02 to U.S. Patent application No. 10/801,985, awarded 10/15/03. European patent No. 1297851 issued 1/26/05. For the use of histone deacytlase inhibitors to up-regulate genes (α -myosin heavy chain, sarcoplasmic reticulum Ca^{2+} ATPase) that are critical to myocardial function and are down-regulated in the failing human heart, and to down-regulate fetal genes (β -MyHC that are up-regulated in pathological hypertrophy. Austrian Patent AT E 287 731 T1: *Inhibition of Histone as a Treatment for Cardiac Hypertrophy* issued September 27, 2002 Spanish Patent 2 236 415: *Inhibition of Histone as a Treatment for Cardiac Hypertrophy* issued September 27, 2002 CU TTO File 2002.054H
7. "Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure." Michael Bristow and Paul Jarosz. Provisional patent filed on 12/12/03. For the optimization of oral formulations of enoximone in the treatment of heart failure. US Patent application No. 10/801,985, allowed 4/29/05. International Patent Application no. PCT/US2004/041806. Fulbright & Jaworski Reference no. MYOG:003WO/10416202.
8. "Methods for treating heart failure with bucindolol based on genetic targeting". and Michael R. Bristow and Stephen B. Liggett. PCT/US/2005/032901 based on U.S serial no. 60/609.689 and 60/610.706 filed 09/14/04; CU TTO # CU1297H.
9. "Methods for treating heart failure with bucindolol based on genetic targeting of the alpha-2c adrenergic receptor. Michael R. Bristow and Stephen Liggett. Provisional Patent Application Serial No. 60/610,706 filed 09/17/04, Docket No. ARCA01 PRO, Hogan & Hartson Reference No. 87877.0006.000.
10. "Diagnosis and Treatment of Myocardial Failure". U.S. Application No. 09/969,086. Date of allowance, 06/28/05.
11. "YY1 and Cardiac Hypertrophy". Carmen Sucharov and Michael R. Bristow. U.S. Provisional Patent Application, Reference No. CU1402H, Docket No. 82-05P, filed 07/22/05.
12. "ERK1/2 and Cardiac Hypertrophy". Carmen Sucharov and Michael R. Bristow. U.S. Provisional Patent Application Reference No. CU1403H, Docket No. 83-05P, filed 07/22/05.
13. PCT Patent Application entitled "Yin Yang 1 as a Treatment for Cardiac Hypertrophy and Heart Failure" (CU TTO File No. CU1402H) PCT Patent Application entitled "Inhibition of Extracellular Signal-Regulated Kinase 1,2 as a Treatment for Cardiac Hypertrophy and Heart Failure" (CU TTO File No. 1403H), filed 7/21/06

O. Academic Interests

Adrenergic mechanisms in heart failure

Receptor-mediated signal transduction

Altered contractile proteins and the expression of fetal genes in myocardial failure and remodeling

Cardiac Resynchronization Therapy as a Treatment for Chronic Heart Failure

P. Publications

Ph.D. Thesis

1. **Bristow MR**: A Quantitative Study of Beta Adrenergic Receptor Mechanisms in Various Tissues of the Rabbit. Ph.D. Thesis, University of Illinois College of Medicine, Department of Pharmacology, 1971.

Books

1. **Bristow MR**, editor: Drug-Induced Heart Disease (Drug-Induced Disease, volume 5). Amsterdam, Biomedical Press, 1980.
2. Hergott L, **Bristow MR**. Treatment Strategies in Cardiovascular Medicine. Pocket Medicine, 2002 (In press).

Book Chapters

1. Billingham ME, **Bristow MR**, Glatstein E, Mason JW, Masek MA, and Daniels JR: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. 1978 Year Book of Cancer.
2. **Bristow MR**: Pathophysiologic basis for cardiac monitoring in patients receiving anthracyclines. In Anthracyclines: Current Status and New Developments, New York, Academic Press, 1980, pp.255–271.
3. **Bristow MR**: Anthracycline cardiotoxicity. In Drug-Induced Heart Disease, ed. By MR Bristow, Amsterdam, Biomedical Press, 1980.
4. Ginsburg R, **Bristow MR**, Harrison DC and Stinson EB: Potential pharmacologic mechanisms involved in coronary artery spasm. In Drug-Induced Heart Disease, MR Bristow, ed., Amsterdam, Biomedical Press, 1980.
5. **Bristow MR**: Protection against doxorubicin cardiomyopathy in rabbits by coenzyme Q₁₀: Evidence for non-specific myocardial preservation. In Biomedical and Clinical and Clinical Aspects of Coenzyme Q. Volume 2, Y Yamamura, K Folkers and Y Ito, eds., Amsterdam, Biomedical Press, 1980, pp.179–188.
6. **Bristow MR**: Evaluation and prevention of anthracycline cardiotoxicity. In Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment. Bristol Myers Cancer Symp. Vol 3, SA Rosenberg and HS Kaplan, eds., pp. 627–638, 1982.
7. Billingham ME, **Bristow MR**, Mason JW and Joseph LJ. Endomyocardial biopsy. In Congestive Heart Failure, E Braunwald, MB Mock and JT Watson, eds. New York, Grune & Stratton, Inc., 1982, pp. 237–251.
8. **Bristow MR**: Drug toxicity and the heart: Potential molecular mechanisms. In Specific Heart Muscle Disease, C Symons, ed. London, John Wright & Son, (in press).
9. Clusin WT, Buchbinder M, **Bristow MR**, and Harrison DC: Evidence for a role of calcium in the genesis of early ischemic cardiac arrhythmias. In Calcium Antagonists and Cardiovascular Disease, LH Opie, ed. New York, Raven Press, 1984, pp. 293–302.
10. **Bristow MR**: Cardiac monitoring of patients receiving anthracycline. In International Symposium on Anthracycline Antibiotics in Cancer Therapy. FM Muggia, ed. Amsterdam, Martinus Nijhoff, Kluwer Academic, 1982.
11. Billingham ME and **Bristow MR**: Endomyocardial biopsy for cardiac monitoring of patients receiving anthracycline. In Endomyocardial Biopsy: Techniques and Applications. J Fenoglio, ed. C.R.C. Press, 1982.
12. Ginsburg R, **Bristow MR**, Schroeder JS, Stinson EB, and Harrison DC: Effects of pharmacologic agents on in vitro human coronary arteries. In Coronary Artery Dynamics, pp. 103–125.
13. O’Connell JB, Renlund DG, Lee HR, Gay WA, **Bristow MR**. Newer techniques of immunosuppression in cardiac transplantation. In Emery RW and Pritzker MR(eds) Cardiac Surgery: State of the Art Reviews. Hanly and Balfus Publishers, Philadelphia, Vol 2, 1988 pp 607-615.
14. **Bristow MR**, Port JD: Receptor pharmacology of the human heart. In Current Concepts in Cardiovascular Physiology, O.B. Garfein, ed., Academic Press, Chapter 2:73–132, 1990.
15. **Bristow MR**, O’Connell JB: Myocardial Diseases. In Textbook of Internal Medicine. Chapter 39:168–176. William N. Kelley, ed. J. B. Lippincott Company, Philadelphia, PA. 1988, 1990, 1996.
16. Gilbert EM, **Bristow MR**: The β -adrenergic receptor-G protein-adenylate cyclase complex in idiopathic dilated cardiomyopathy. In Advances in Cardiomyopathies. Pp. 235–250. Baroldi G, Camerini F, Goodwin JR, eds. Springer-Verlag, Germany, 1990.

17. Feldman AM, **Bristow MR**: Adrenergic neuroeffector mechanisms in the failing human heart. Chapter 9:206–216. In Heart Disease, Third Edition: Clinical Update. Braunwald E, ed. W.B. Saunders Co., 1990.
18. **Bristow MR**, Renlund DG, O’Connell JB. The Current Status of cardiac transplantation. In: Cortina A, Moris C, Lambert JLR, Cortina R (eds). Congestive Heart failure: Pathophysiologic Bases and Therapeutic Implications, Prous Science, Oviedo Spain, 1992, pp. 125-132.
19. O’Connell JB, **Bristow MR**, Renlund DG. The use of OKT3 for induction therapy in cardiac transplantation. Chapter 3:37–46. In A Critical Analysis of Monoclonal Antibody Therapy in Transplantation. WJ Burlingham, ed. CRC Press, Inc., Boca Raton, Florida, Pp. 37-46. 1992.
20. Renlund DG, Olsen SL, Ensley RD, **Bristow MR**. Future improvements in immunosuppression following cardiac transplantation. In Intrathoracic Transplantation, Surgery/2000, Kaye MP and O’Connell JB eds, RG Landes Company, Georgetown Texas, pp 95-102, 1993.
21. **Bristow MR**, Movsesian M, Feldman AM. β -adrenergic receptor dysfunction in the pathogenesis of idiopathic dilated cardiomyopathy. In Symposia on Idiopathic Dilated Cardiomyopathy. HR Figula, ed. Springer-Verlag, Berlin, pp 210-221, 1993.
22. Gilbert EM, **Bristow MR**. Idiopathic Dilated Cardiomyopathy. Chapter 89. In Textbook of Cardiology. Hurst, ed. McGraw-Hill, Inc., New York, NY, 1994.
23. Lowes BD, Abraham WT, **Bristow MR**. Role of beta blockers in the treatment of heart failure. In Heart Disease: Update. E Braunwald, ed. WB Saunders Co. 1994.
24. Port JD, Pende A, Valent S, **Bristow MR**. Adrenergic Receptors: Relevance to Myocardial Signal Transduction in Heart Failure. Chapter 1. Perspective in Cardiac Insufficiency. Pp 8-19. J. Del Cas, ed. CV Leier, ed. UTET 1995.
25. Abraham WT, Port JD, **Bristow MR**. Neurohormonal receptors in the failing human heart. In: Heart Failure:Scientific Principles and Clinical Practice. Poole-Wilson PA, Chatterjee K, Coats AJS, WS, Massie, eds. New York: Churchill Livingstone. Pp. 127-144. 1996.
26. Renlund DG, **Bristow MR**, Taylor. Cardiac transplantation: recipient selection and management. In Therapeutic Immunology. Austen KD, Burakoff SJ, Rosen FS, and Strom TB, eds. Blackwell Science, Cambridge, MA. Pp. 469-473. 1996.
27. Wolfel EE, **Bristow MR**. Effects of long-term beta-adrenergic blockade on exercise capacity in patients with chronic heart failure. Chapter 8. In: Exercise and Heart Failure. Pp. 141-170. Balady GJ, Piña IL, eds. Armonk, New York: Futura Publishing, 1997.
28. **Bristow MR**, Bohlmeyer TJ, Gilbert EM. Dilated Cardiomyopathy. Chapter 73. In Hurst’s the Heart, eds Alexander RW, Schlant RC, Sonnenblick EH, O’Rourke RA, Roberts R. McGraw-Hill, Inc., New York, NY, 1998.
29. **Bristow MR**. Cardiology. In Case-Oriented Problems in Internal Medicine. Little, Brown & Co., 1999.
30. **Bristow MR**. Treatment of dilated cardiomyopathies with β -adrenergic blocking agents. In Advances in Cardiomyopathies pp236-244, eds Camerini F, Gavazzi A, DeMaria R. Springer, Milano Italy, 1999.
31. Lindenfeld J, Mann DE, **Bristow MR**. Chapter 2. Cardiology. The Internal Medicine Casebook: Real Patients, Real Answers. Lippencott Williams & Wilkens, 1999.
32. **Bristow MR**, Mestroni L, Bohlmeyer T, Gilbert EM. Chapter 66. Dilated Cardiomyopathies. Hurst’s the Heart, 10th Edition, McGraw-Hill NY, pp 1947-1966, 2001.
33. **Bristow MR**, Port JD, Kelly RA. Chapter 18. Treatment of heart failure: pharmacologic methods. In Heart Disease. A textbook of Cardiovascular Medicine, 6th edition. Ed Braunwald E, Zipes DP, Libby P. WB Saunders, Philadelphia 2001.
34. **Bristow MR**. Chapter 21. Management of heart failure. In Heart Disease. A textbook of Cardiovascular Medicine, 6th edition. Ed Braunwald E, Zipes DP, Libby P. WB Saunders, Philadelphia 2001.
35. **Bristow MR**, Port JD, Kelley R, Pharmacologic Management of Congestive Heart Failure. In: Cardiovascular Therapeutics 2nd Edition: A Companion to Braunwald’s Heart Disease. Antman, E.M., ed. W.B. Saunders Co. 2001.
36. Hergott L, **Bristow MR**. (Eds.) Treatment Strategies in Cardiovascular Medicine. New York: PocketMedicine.com; 2002.
37. Tsvetkova T, **Bristow MR**. Pathophysiology of Chronic Heart Failure. In Oxidative Stress and Cardiac Failure, eds Kukin M, Fuster V, 2002.

38. Port JD, Linseman JV, **Bristow MR**. Adrenergic Receptor Signaling in Chronic Heart Failure. *Heart Failure: A companion to Braunwald's Heart Disease*. Ed Mann, DL; 2002.
39. **Bristow MR**, Lowes BD. Management of Heart Failure. In *Heart Disease. A textbook of Cardiovascular Medicine*, 7th edition. Ed Braunwald E, Zipes DP, Libby P. WB Saunders, Philadelphia 2004.
40. **Bristow MR**, Linas S, Port JD. Treatment of heart failure: pharmacologic methods. In *Heart Disease. A textbook of Cardiovascular Medicine*, 7th edition. Ed Braunwald E, Zipes DP, Libby P. WB Saunders, Philadelphia 2004.
41. Mestroni, L Bohlmeier T, Gilbert EM, Bristow MR. Dilated Cardiomyopathies. *Hurst's the Heart*, 11th Edition, McGraw-Hill NY, 2004.
42. Robinson P, Bristow MR. Beta Blockers. In: *The Pharmacologic Management of Chronic Heart Failure*. Ed Feldman, AM, Blackwell Publishing, 2005.
43. Port JD, **Bristow MR**. Adrenergic receptor coupling and uncoupling in heart failure. *A textbook of Molecular Mechanisms of Cardiac Hypertrophy and Failure*. Ed. Richard A Walsh M.D. Taylor and Francis 2005.

Editorials

1. **Bristow MR**. Ginsburg R and Harrison DC: Histamine and the human heart: The other receptor system. *Amer J Cardiol* 49:249–251,1982.
2. **Bristow MR**. Cardiotoxic effects of anthracyclines. *Western J Med* 139:369–371,1983.
3. **Bristow MR**. The Adrenergic Nervous System in Heart Failure. *N Engl J Med* 311(13):850–851,1984.
4. **Bristow MR**. Myocardial cell surface membrane receptors in heart failure. *Heart Failure* 5:47–50, 1989.
5. **Bristow MR**. The surgically denervated, transplanted human heart. *Circulation* 82:658–660, 1990.
6. Abraham WT, **Bristow MR**. Specialized Centers for Heart Failure Management. *Circulation*. 96:2755-2757, 1997.
7. **Bristow MR**. Tumor Necrosis Factor- α and cardiomyopathy. *Circulation*. 97:1340-1341, 1998.
8. **Bristow MR**. What type of β -blocker should be used to treat chronic heart failure? *Circulation* 102:484-486, 2000.
9. **Bristow MR**. Etomoxir: a new approach to treatment of chronic heart failure. *Lancet* 356(9242)1621-22, 2000.
10. **Bristow MR**. Of phospholamban, mice and humans with heart failure. *Circulation* 103:1-2, 2001.
11. Eichhorn EJ, **Bristow MR**. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. *Curr Control Trials Cardiovasc Med* 2:20-23, 2001.
12. **Bristow MR**, Long CS. Cardiotrophin-1 in heart failure. *Circulation* 106 (12):1430-1432, 2002
13. Linseman JV, **Bristow MR**. Drug therapy and heart failure prevention. *Circulation* 107:1234-1236, 2003.
14. **Bristow MR**. Microarray measurements of gene expression before and after LVAD placement. *J Am Coll Cardiol* 41:1107-1108, 2003.

Letters

1. **Bristow MR**. β -blocker-vasodilator treatment of hypertension. (Letter) *New Engl J Med* 282:1102,1970.
2. **Bristow MR**, Mason JW, Daniels JR. Use of the myocardial biopsy to monitor cardiotoxicity. (Letter) *Cancer Treat Rep* 62:1067–1068,1978.
3. Ginsburg R, Stinson EB, **Bristow MR**, Schroeder JS. Coronary-artery spasm after revascularization. (Letter) *New Engl J Med* 305(12):699,1981.
4. Feldman AM, **Bristow MR**, Parmley WW. Vesnarinone morbidity and mortality in patients with heart failure. *N Engl J Med* 329(3):149–155, 1993.
5. Raynolds MV, Perryman MB, **Bristow MR**. (Letter, authors' reply to) Circulating ACE concentrations and progression of heart disease (JC Woodrow). *The Lancet* 343:353–354, 1994.
6. Kinugawa K, Long CS, **Bristow MR**. Expression of TR isoforms in failing human heart. *J Clin Endocrinol Metab* 86(10):5089-90, 2001.

Monographs

1. Monoclonal Antibody Therapy. New approaches to immunosuppression in cardiac transplantation. Kaye MP, **Bristow MR**, Rose E, Starnes V, eds. Pro/Com. 1988.
2. Feldman AM, **Bristow MR**. Evolving Issues in Heart Failure. The β -adrenergic pathway in the failing human heart: Implications for inotropic therapy. Merrell Dow Pharmaceuticals, Inc. Cincinnati, OH. 1989.
3. **Bristow MR**. Lowering of cardiac adrenergic drive by lisinopril in heart failure. A Focus on the Clinical Effects of a Long-Acting ACE Inhibitor/Heart Failure. Nicholls MG, ed., Raven Press, Ltd. New York, 1990.

Symposia or Workshops Chaired and Edited, with Published Summary or Introduction

1. Colucci WS, **Bristow MR**. Beta-blocker therapy for heart failure: rationale, potential mechanisms and clinical trial experience. *Am J Cardiol* 80(11A):1L, 1997.
2. **Bristow MR**. Best practices for optimal treatment of advanced heart failure. *Clin Cardiol* 23(Supplement III): III-IV, 2000.
3. **Bristow MR** et al. (Jeffrey Towbin, Co-Chair) NHLBI Workshop on Genetic Determinants of Response to Drug Therapy for Heart failure, Bethesda MD 9/9-9/10/2002, Ms in preparation.

Journal Articles

1. **Bristow MR**, Sherrod TR and Green RD: Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach, and trachea. *J Pharmacol Exp Ther* 171:52–61, 1970.
2. **Bristow MR** and Green RD: A quantitative study of beta-adrenergic receptors in rabbit atria. *Europ J Pharmacol* 12:120–123, 1970.
3. Green RD, Lefever GS, Sheys EM, and **Bristow MR**: On the specificity of alpha-adrenergic receptor labeling by ^{14}C -dibenzamine. *J Pharmacol Exp Ther* 187:524–528, 1973.
4. Billingham ME, **Bristow MR**, Glatstein J, Mason JW, Masek MA and Daniels JR: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. *Amer J Surg Path* 1:17–23, 1977.
5. **Bristow MR** and Green RD: Effect of diazoxide, verapamil and compound D600 on isoproterenol and calcium-mediated dose-response relationships in isolated rabbit atrium. *Europ J Pharmacol* 45:267–279, 1977.
6. **Bristow MR**, Schwartz HD, Binetti G, Harrison DC and Daniels JR: Ionized calcium and the heart: Elucidation of in vivo concentration-response relationships in the open-chest dog. *Circ Res* 41:565–574, 1977.
7. **Bristow MR**, Daniels JR, Kernoff RS and Harrison DC: Effect of compound D600, practolol and alterations in magnesium on ionized calcium relationships in the intact dog heart. *Circ Res* 41:574–581, 1977.
8. **Bristow MR**, Mason JW, Billingham ME and Daniels JR: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. *Ann Int Med* 88:168–175, 1978.
9. **Bristow MR**, Billingham ME, Mason JW and Daniels JR: The clinical spectrum of anthracycline antibiotic cardiotoxicity. *Cancer Treat Rep* 62:873–879, 1978.
10. Billingham ME, Mason JW, **Bristow MR** and Daniels JR: Anthracycline cardiomyopathy monitored by morphological changes. *Cancer Treat Rep* 62:865–872, 1978.
11. Mason JW, **Bristow MR**, Billingham ME and Daniels JR: Invasive and noninvasive methods of assessing adriamycin cardiotoxicity in man: Superiority of histopathologic assessment using endomyocardial biopsy. *Cancer Treat Rep* 62:857–864, 1978.
12. **Bristow MR**, Thompson PD, Martin RP, Mason JW, Billingham ME and Harrison DC: Early anthracycline cardiotoxicity. *Amer J Med* 65:823–832, 1978.
13. **Bristow MR**, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH and Daniels JR: Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. *J Cardiovasc Pharmacol* 2:487–515, 1980.
14. Ginsburg R, **Bristow MR**, Stinson EB, and Harrison DC: Histamine receptors in the human heart. *Life Sciences* 26:2245–2249, 1980.

15. Ginsburg R, **Bristow MR**, Harrison DC, and Stinson EB: Studies with isolated human coronary arteries: Some general observations, potential mediators of spasm, role of calcium antagonists. *Chest* 78:180S–186S, 1980.
16. **Bristow MR**, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, and Daniels JR: Anthracycline-associated cardiac and renal damage in rabbits: Evidence for mediation by vasoactive substances. *Lab Invest* 45:157–168, 1981.
17. Ginsburg R, **Bristow MR**, Kantrowitz N, Baim DS, and Harrison DC: Histamine provocation of clinical coronary artery spasm: Implications concerning pathogenesis of variant angina pectoris. *Am Heart J* 102:819–822, 1981.
18. Ginsburg R, Lamb I, **Bristow MR**, and Schroeder JS: Application and safety of outpatient ergonovine testing in accurately detecting coronary spasm in patients with possible variant angina. *Am Heart J* 102:698–702, 1981.
19. **Bristow MR**, Mason JW, Billingham ME, and Daniels JR: Dose-effect and structure function relationships in doxorubicin cardiomyopathy. *Am Heart J* 102:709–718, 1981.
20. **Bristow MR**, Lopez MB, Mason JW, Billingham ME, and Winchester MA: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. *Cancer* 50(1):32–41, 1982.
21. **Bristow MR**, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB: Decreased catecholamine sensitivity and β -adrenergic-receptor density in failing human hearts. *New Engl J Med* 307:205–211, 1982.
22. **Bristow MR**, Cubicciotti R, Ginsburg R, Stinson EB, and Johnson C: Histamine-mediated adenylate cyclase stimulation in human myocardium. *Mol Pharmacol* 21:671–679, 1982.
23. Clusin WT, **Bristow MR**, Jaillon P, Schroeder JS, Brett P, Baim DS, and Harrison DC: The effects of diltiazem and reduced serum ionized calcium on the latency of ischemic ventricular fibrillation in the dog. *Circ Res* 50:518–526, 1982.
24. **Bristow MR**, Ginsburg R, Kantrowitz NE, Baim DS, and Rosenbaum JT: Coronary spasm associated with urticaria: Report of a case mimicking anaphylaxis. *Clin Cardiol* 5:238–240, 1982.
25. Clusin WT, **Bristow MR**, Karagueuzian HS, Katzung and Schroeder JS: Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? *Am J Cardiol* 49:606–612, 1982.
26. Schroeder JS, Lamb IH, Ginsburg R, **Bristow MR**, and Hung J: Diltiazem for long-term therapy of coronary arterial spasm. *Amer J Cardiol* 49:533–537, 1982.
27. Kantrowitz NE, **Bristow MR**, Minobe WA, Billingham ME, and Harrison DC: Histamine-mediated myocardial damage in rabbits. *J Mol Cell Cardiol* 14:551–555, 1982.
28. Lurie KG, Billingham ME, Masek MA, Ginsburg R, and **Bristow MR**: Ultrastructural and functional studies on prolonged myocardial preservation in an experimental heart transplant model. *J Thor and Cardiovasc Surg* 84:122–129, 1982.
29. **Bristow MR**. Toxic cardiomyopathy due to doxorubicin. *Hospital Practice* 17:101–111, 1982.
30. McKillop JH, **Bristow MR**, Goris ML, Billingham ME, and Bockemuehl K: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. *Amer Heart J* 105:1048–1056, 1983.
31. Ginsburg R, **Bristow MR**, Billingham ME, Stinson EB, Schroeder JS, and Harrison DC: Study of the normal and failing isolated human heart: Decreased response of failing heart to isoproterenol. *Am Heart J* 106:535–540, 1983.
32. Liu ET, **Bristow MR**, Stone MJ, Willerson MD: Serum myoglobin, ionized calcium and parathyroid function during rhabdomyolysis. *Arch Intern Med* 143:154–157, 1983.
33. Kantrowitz NE, **Bristow MR**. Heart muscle disease: The biomechanics of congestive heart failure. *Primary Cardiology* 9(6):116–124, 1983.
34. Lurie KG, **Bristow MR**, and Reitz BA: Increased β -adrenergic receptor density in an experimental model of cardiac transplantation. *J Thor Cardiovasc Surg* 86(2):195–201, 1983.
35. Ginsburg R, Esserman L, and **Bristow MR**. Myocardial performance and extracellular ionized calcium in a severely failing human heart. *Ann Intern Med* 98:603–606, 1983.

36. Ginsburg R, Davis K, **Bristow MR**, McKennett K, Kodsi SR, Billingham ME, Schroeder JS. Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. *Lab Invest* 49(2):154–158, 1983.
37. Schroeder JS, Lamb IH, **Bristow MR**, Ginsburg R, Hung J, McAuley BJ. Prevention of cardiovascular events in variant angina by long-term diltiazem therapy. *J Am Col Cardiol* 1(6):1507–1511, 1983.
38. **Bristow MR**, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, and Billingham ME: Prevention of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. *J Cardiovasc Pharm* 5:913–919, 1983.
39. Torti FM, **Bristow MR**, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown WB, and Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. *Annals Int Med* 99:745–749, 1983.
40. Tsujimoto G, **Bristow MR**, and Hoffman BB. Identification of alpha₁ adrenergic receptors in rabbit aorta with ¹²⁵I]BE2254. *Life Sciences* 34:639–646, 1984.
41. Ginsburg R, **Bristow MR**, Davis K, Billingham ME, Dibiase A, and Harrison DC. Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries. *Circulation* 69(2)430–440, 1984.
42. **Bristow MR**, Ginsburg R, Laser JA, McAuley BJ, and Minobe WA: Tissue response selectivity of calcium antagonists is not due to heterogeneity of [³H]-nitrendipine binding sites. *Brit J Pharmacology* 82:309–320, 1984.
43. Billingham ME, and **Bristow MR**. Evaluation of anthracycline cardiotoxicity: Predictive ability and functional correlation of endomyocardial biopsy. *Cancer Treat Rep* 3:71–76, 1984.
44. **Bristow MR**. Myocardial β-adrenergic receptor downregulation in heart failure. *Int J Cardiol* 5:648–652, 1984.
45. **Bristow MR**, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. *J Clin Invest* 74:212–223, 1984.
46. Kantrowitz NE, **Bristow MR**. Cardiotoxicity of antitumor agents. *Prog Cardiovasc Dis* 3:195–200, 1984.
47. Ginsburg R, **Bristow MR**, Davis K. Receptor mechanisms in the human epicardial coronary artery: Heterogeneous pharmacological response to histamine and carbachol. *Circ Res* 55(3):416–421, 1984.
48. Fowler MB and **Bristow MR**. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. *Am J Cardiol* 55(10)D120–D124, 1985.
49. **Bristow MR**, Kantrowitz NE, Ginsburg R, and Fowler MB. β-adrenergic function in heart muscle disease and heart failure. *J Mol Cell Cardiol* 17 (Supp 2):41–52, 1985.
50. Hunt SC, McCarron DA, Smith JB, Ash KO, **Bristow MR**, Williams RR. The relationship of plasma ionized calcium to cardiovascular disease endpoint and family history of hypertension. *Clin Exp A* 6(8)1397–1414, 1985.
51. Torti FM, **Bristow MR**, Lum BL, Carter SK, Howes AE, Aston DA, Brown BW, Hannigan JF, Meyers FJ, Mitchell EP, Billingham ME. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. *Cancer Res* 46:3722–3727, 1986.
52. **Bristow MR** and Ginsburg R: β₂ receptors on myocardial cells in human ventricular myocardium. *Am J Cardiol* 57:3F–6F, 1986.
53. **Bristow MR**, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, and Stinson EB: β₁—and β₂-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β₁-receptor down-regulation in heart failure. *Circ Res* 59:297–309, 1986.
54. Schroeder JS, Scott LB, Ginsburg R, **Bristow MR**: Efficacy of diltiazem for medically-refractory stable angina: Longterm follow-up. *Clin Cardiol* 8(9):480–485, 1986.
55. Freter CE, Lee TC, Billingham ME, Chak L, **Bristow MR**: Doxorubicin cardiac toxicity manifesting seven years after treatment. *Amer J Med* 80:483–485, 1985.
56. Burton NA, Gay WA, Jones KW, **Bristow MR**, Karwande SV, Doty DB, Sorenson SG, Burke JL, Anderson JA, Lappe DL, Laser JA, Eiswirth CC, Gilbert EM: Heart transplantation in Utah: Results in a multiinstitutional program. *J Heart Transplantation* 5:69–70, 1986.

57. Khan MM, Marr-Leisy D, Verlander MS, **Bristow MR**, Strober S, Goodman M, Melmon KL: The effects of derivatives of histamine on natural suppressor cells. *J Immunol* 137(1):308–314, 1986.
58. Fowler MB, Laser JA, Hopkins GL, Minobe W, **Bristow MR**: Assessment of the β -adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response. *Circulation* 74(6):1290–1302, 1986.
59. Gilbert EM, DeWitt CW, Eiswirth CC, Renlund DG, Menlove RL, Freedman LA, Herrick CM, Gay WA, **Bristow MR**: Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. *Amer J Med* 82:202–206, 1987.
60. Gilbert EM, Eiswirth CC, Renlund DG, Menlove RL, DeWitt CW, Freedman LA, Herrick CM, Gay WA, **Bristow MR**: Use of ORTHOCLONE OKT3 monoclonal antibody in cardiac transplantation: Early experience with rejection prophylaxis and treatment of refractory rejection. *Transplant Proc* 19(2) Suppl 1:45–53, 1987.
61. Renlund DG, **Bristow MR**, Gay WA and The UTAH Cardiac Transplant Program. Survival following cardiac transplantation. *Western J Med* 146:627–630, 1987.
62. Renlund DG, **Bristow MR**, Lybbert MR, O’Connell JB, Gay WA. Medicare-designated centers for cardiac transplantation. *NEJM* 316:873–876, 1987.
63. Renlund DG, O’Connell JB, Gilbert EM, Watson FS, **Bristow MR**. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. *J Heart Transplant* 6:71–78, 1987.
64. Gilbert EM, **Bristow MR**, Mason JW: The acute hemodynamic response to low dose enoximone (MDL 17,043): An oral dose-range study. *Amer J Cardiol* 82:57c-62C, 1987.
65. Renlund DG, Gilbert EM, O’Connell JB, Gay WA, Jones KW, Burton NA, Doty DB, Karwande SV, Dewitt CW, Menlove RL, Herrick CM, **Bristow MR** and The UTAH Cardiac Transplant Program. Age-associated decline in cardiac allograft rejection. *Am J Med* 83(3):391–398, 1987.
66. **Bristow MR**, Ginsburg R, Gilbert EM, Hershberger RE. Heterogeneous regulatory changes in cell surface membrane receptors coupled to a positive inotropic response in the failing human heart. *Basic Res Cardiol* 82 (Suppl 2):369–376, 1987.
67. Gilbert EM, Renlund DG, O’Connell JB, Eiswirth CC, Rothstein G, Gay WA, **Bristow MR**. Immunosuppressive efficacy of vincristine in cardiac transplantation: A preliminary report. *J Heart Transplant* 6:369–374, 1987.
68. **Bristow MR**, Gilbert EM, Renlund DG, DeWitt CW, Burton NA, O’Connell JB. Use of OKT3 monoclonal antibody in heart transplantation: Review of the initial experience. *J Heart Transplant* 7:1–11, 1988.
69. **Bristow MR**, Gilbert EM, O’Connell JB, Renlund DG, Watson FS, Hammond E, Lee RG, Menlove R and the Utah Cardiac Transplant Program. OKT3 monoclonal antibody in heart transplantation. *Amer J Kidney Disease* 11:135–140, 1988.
70. Gilbert EM, O’Connell JB, Hammond EH, Renlund DG, Watson FS, **Bristow MR**. Treatment of myocarditis with OKT3 monoclonal antibody. *Lancet* 2:759, 1988.
71. Watson FS, O’Connell JB, Amber IJ, Renlund DG, Classen D, Johnston JM, Smith CB, **Bristow MR**, and the UTAH Cardiac Transplant Program. Treatment of cytomegalovirus pneumonia in cardiac transplant recipients with 9(1,3-dihydroxy-2-propoxymethyl)-guanine (DHPG). *J Heart Transplant* 7(2):102–105, 1988.
72. Hershberger RE, **Bristow MR**. Receptor alterations in failing human heart. *Heart Failure* 3(6):230–238, 1988.
73. Yowell RL, Hammond EH, **Bristow MR**, Watson FS, Renlund DG, O’Connell JB. Acute vascular rejection involving the major coronary arteries of a cardiac allograft. *J Heart Transplant* 7:191–197, 1988.
74. Gilbert EM, Krueger SK, Murray JL, Renlund DG, O’Connell JB, Gay WA, **Bristow MR**. Echocardiographic evaluation of potential cardiac transplant donors. *J Thorac Cardiovasc Surg* 95:1003–1007, 1988.
75. Wittwer CT, **Bristow MR**, Gilbert EM, Renlund DG, O’Connell JB, DeWitt CW. OKT3 therapy as a cause of high panel-reactive antibodies in serum using standard microcytotoxicity techniques. *Transplantation* 45:832-834, 1988.
76. **Bristow MR**. The β -adrenergic receptor: Configuration, regulation, mechanism of action. *Postgraduate Medicine: A Special Report*. 83:19-26, 1988.

77. Anderson FL, Kralios AC, Hershberger RE, **Bristow MR**. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: Comparison with isoproterenol and forskolin. *J Cardiovasc Pharmacol* 12:365–371, 1988.
78. Renlund DG, **Bristow MR**, Lee HR, O'Connell JB. Medical aspects of cardiac transplantation. *J Cardiothoracic Anesthesia* 11(4):500–512, 1988.
79. Feldman AM, Cates AE, Veazey WB, Hershberger RE, **Bristow MR**, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. *J Clin Invest* 82:189–197, 1988.
80. Lurie KG, **Bristow MR**, Minobe WA, Masek M, Billingham ME. 6-Hydroxydopamine mediated cardiotoxicity in rabbits. *Amer J Cardiovasc Pathol* 2(2):181–191, 1988.
81. **Bristow MR**, Renlund DG, Gilbert EM, Lee HR, Gay WA, O'Connell JB and the UTAH Cardiac Transplant Program. Murine monoclonal CD-3 antibody in cardiac transplantation: Antirejection treatment and preliminary results in a prospectively randomized trial for prophylaxis. *Clin Transplantation* 2:163–168, 1988.
82. **Bristow MR**, Sandoval AB, Gilbert EM, Deisher T, Minobe W, Rasmussen R. Myocardial α - and β -adrenergic receptors in heart failure: Is cardiac derived norepinephrine the regulatory signal? *European Heart J* 9:35–40, 1988.
83. Anderson FL, Kralios AC, Hershberger R, **Bristow MR**. Desensitization of myocardial but not coronary VIP receptor-mediated responses in dogs. *Am J Physiol* 255:H601–H607, 1988.
84. Gay WA, O'Connell JG, Burton NA, Karwande SV, Renlund DG, **Bristow MR**. OKT3 monoclonal antibody in cardiac transplantation: Experience with 102 patients. *Ann Surg* 208(3):287–290, 1988.
85. Renlund DG, **Bristow MR**, O'Connell JB. Cardiac transplantation: The need for prospective, randomized, controlled investigations. *West J Med* 149:583–585, 1988.
86. O'Connell JB, Renlund DG, Lee HR, Gay WA, **Bristow MR**. Newer techniques of immunosuppression in cardiac transplantation. *Cardiac Surgery* 2:607–615, 1988.
87. O'Connell JB, Renlund DG, Robinson JA, Fowler MB, Oyer PE, Pifarre R, Grady KL, Mullin AV, Menlove RL, Gay WA, **Bristow MR**. Effect of preoperative hemodynamic support on survival after cardiac transplantation. *Circulation* 78(Suppl III):78–82, 1988.
88. Crandall BG, Renlund DG, O'Connell JB, Burton NA, Jones KW, Gay WA, Doty DB, Karwande SV, Lee HR, Holland C, Menlove RL, Hammond ME, **Bristow MR**. Increased cardiac allograft rejection in female heart transplant recipients. *J Heart Transplant* 7:419–423, 1988.
89. **Bristow MR**, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. *J Pharmacol Exp Ther* 247:1039–1045, 1988.
90. Gilbert EM, Eiswirth CC, Mealey PC, Larrabee P, Herrick CM, **Bristow MR**. β -adrenergic supersensitivity of the transplanted human heart is presynaptic in origin. *Circulation* 79:344–349, 1989.
91. Heilbrunn SM, Shah P, **Bristow MR**, Valantine HA, Ginsburg R, Fowler MB. Increased β -receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. *Circulation* 79:483–490, 1989.
92. **Bristow MR**, Hershberger RE, Port JD, Minobe W, Rasmussen R. β_1 - and β_2 -adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. *Mol Pharm* 35:295–303, 1989.
93. Feldman AM, Cates AE, **Bristow MR**, Van Dop C. Altered expression of α -subunits of G proteins in failing human hearts. *J Mol Cell Cardiol* 21:359–365, 1989.
94. O'Connell JB, Renlund DG, **Bristow MR**. Cardiac transplantation: Emerging role of the internist/cardiologist. *J Internal Med* 225:147–156, 1989.
95. Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, Karwande SV, Doty DB, Menlove RL, Herrick CM, Lee HR, Gay WA, **Bristow MR**. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. *Transplantation* 47:599–605, 1989.
96. **Bristow MR**, Port JD, Sandoval AB, Rasmussen R, Ginsburg R, Feldman AM. Beta-adrenergic receptor pathways in the failing human heart. *Heart Failure* 5:77–90, 1989.

97. Gilbert EM, Port JD, Hershberger RE, **Bristow MR**. Clinical significance of alterations in the β -adrenergic receptor-adenylate cyclase complex in heart failure. *Heart Failure* 5:91–98, 1989.
98. Hershberger RE, Anderson FL, **Bristow MR**. Vasoactive intestinal peptide receptor pharmacology in nonfailing and failing human heart. *Heart Failure* 5:51–61, 1989.
99. **Bristow MR**, Lee HR, Gilbert EM, Renlund DG, Hegewald MG, Hershberger RE, O'Connell JB. Use of enoximone in patients awaiting cardiac transplant. *Br J Clin Practice* 64:69–72, 1989.
100. O'Connell JB, Renlund DG, Gay WA, DeWitt CW, Hammond EH, Yowell RL, Jones KW, Karwande SV, Doty DB, **Bristow MR**. Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. *Transplantation* 47:788–792, 1989.
101. Witwer CT, Knape WA, **Bristow MR**, Gilbert EM, Renlund DG, O'Connell JB, DeWitt CW. Quantitative flow cytometric plasma OKT3 assay: Potential application in cardiac transplantation. *Transplantation* 48:533–535, 1989.
102. Renlund DG, **Bristow MR**, Crandall BG, Burton NA, Doty DB, Karwande SV, Gay WA, Jones KW, Hegewald MG, Lee HR, O'Connell JB and the UTAH Cardiac Transplant Program. Hypercholesterolemia after heart transplantation: Amelioration by corticosteroid-free maintenance immunosuppression. *J Heart Transplant* 8:214–220, 1989.
103. Shaddy RE, Mak C, **Bristow MR**. Comparative in vitro myocardial inotropic effects and in vivo hemodynamic effects of forskolin and isoproterenol in young lambs. *Pediatric Res* 25:580–584, 1989.
104. Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, **Bristow MR**. OKT3 monoclonal antibody given for 10 versus fourteen days as immunosuppressive prophylaxis in heart transplantation. *J Heart Transplant* 8:303–10, 1989.
105. Brodde OE, Michel MC, Gordon EP, Sandoval A, Gilbert EM, **Bristow MR**. β -adrenoceptor regulation in the human heart: Can it be monitored in circulating lymphocytes? *Eur Heart J* 10:2–10, 1989.
106. **Bristow MR**, Port JD, Hershberger RE, Gilbert EM, Feldman AM. The β -adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. *Eur Heart J* 10:45–54, 1989.
107. Hershberger RE, Anderson FL, **Bristow MR**. Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density. *Circ Res* 65:283–294, 1989.
108. Movsesian MA, **Bristow MR**, Krall J. Ca^{2+} uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. *Circ Res* 65:1141–1144, 1989.
109. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, **Bristow MR**, Gay WA, Jones KW, O'Connell JB. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. *J Heart Transplant* 8:430–443, 1989.
110. O'Connell JB, Renlund DG, **Bristow MR**. Murine monoclonal CD3 antibody (OKT3) in cardiac transplantation: Three-year experience. *Transplant Proc* 21:31–33, 1989.
111. **Bristow MR**, Gilbert EM. Anti-adrenergic actions of angiotensin converting enzyme inhibitors. *Current Opinion in Cardiol* 4 (Suppl 2): 45–50, 1989.
112. **Bristow MR**, Port JD, Gilbert EM. The role of adrenergic receptor regulation in the treatment of heart failure. *Cardiovascular Drugs and Therapy* 3:971–978, 1989.
113. Kantrowitz NE, Ellis AK, **Bristow MR**, Minobe W, Billingham ME, Harrison DC. Histamine mediates myocardial damage by an H_1 mechanism independent of coronary blood flow. *J Cardiovasc Pharm* 15:82–88, 1990.
114. Port JD, Gilbert EM, Larrabee P, Mealey PS, Volkman K, Ginsburg R, Hershberger RE, **Bristow MR**. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. *Circulation* 81:929–938, 1990.
115. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, **Bristow MR**. Long-term β -blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. *Amer J Med* 88:223–229, 1990.
116. Rasmussen RP, Minobe W, **Bristow MR**. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. *Biochem Pharm* 39:691–696, 1990.

117. Hammond EH, Watson FS, **Bristow MR**, O'Connell JB, Gilbert EM, Doty DB, Renlund DG. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3). *J Heart Transplant* 9:236–238, 1990.
118. Hershberger RE, Wynn JR, Sundberg L, **Bristow MR**. Mechanism of action of bucindolol in human ventricular myocardium. *J Cardiovasc Pharm* 15:959–967, 1990.
119. Feldman AM, **Bristow MR**. The beta adrenergic pathway in the failing human heart: implications for inotropic therapy. *Cardiology* 77 (Suppl 1):1–32, 1990.
120. Ratkovec RM, Wray RB, Renlund DG, O'Connell JB, **Bristow MR**, Gay WA, Karwande SV, Doty DB, Millar RC, Menlove RL, Burke JL, Lappe DL, Tsagaris TJ, Sutton RB, Jones KW. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease following cardiac transplantation. *J Thoracic Cardiovasc Surg* 100:6–12, 1990.
121. Crandall BG, Gilbert EM, Renlund DG, Menlove RL, Herrick CM, Holland CS, Hagan MB, Rasmussen LG, Karwande SV, O'Connell JB, **Bristow MR**. A randomized trial of the immunosuppressive efficacy of vincristine in cardiac transplantation. *Transplantation* 50:34–38, 1990.
122. **Bristow MR**, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. β -adrenergic pathways in nonfailing and failing human ventricular myocardium. *Circulation* 82: Suppl I)12–25, 1990.
123. Renlund DG, O'Connell JB, **Bristow MR**. Strategies of immunosuppression in cardiac transplantation. *Seminars in Thoracic Cardiovasc Surg* 2:181–188, 1990.
124. O'Connell JB, **Bristow MR**, Rasmussen LG, Ratkovec RM, Gay WA, Jones KW, Renlund DG. Cardiac allograft function with corticosteroid-free maintenance immunosuppression. *Circulation* 82(Suppl IV):318–321, 1990.
125. Olsen SL, O'Connell JB, **Bristow MR**, Renlund DG and the Utah Cardiac Transplant Program. Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. *Transplantation* 50:773–775, 1990.
126. Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove RL, Craven C, Renlund DG, **Bristow MR**, DeWitt CW, O'Connell JB. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. *Transplantation* 50:776–782, 1990.
127. Woodley SL, Renlund DG, O'Connell JB, **Bristow MR**. Immunosuppression following cardiac transplantation. *Cardiology clinics* 8:83-96, 1990
128. Cohn JN, Rajfer SI, **Bristow MR**, and attendees. Evaluation of functional capacity in heart failure: A consensus conference. *Heart Failure* Oct/Nov:169–173, 1991.
129. Ensley RD, Hammond EH, Renlund DG, Yowell RL, **Bristow MR**, DeWitt CW, Menlove RM, Ratkovec RM, O'Connell JB. Clinical manifestations of vascular rejection in cardiac transplantation. *Transplant Proceed* 23:1130–1132, 1991.
130. Moore CK, O'Connell JB, Renlund DG, **Bristow MR**, Hammond EH. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization. *Transplant Proceed* 23:1055–1058, 1991.
131. O'Connell JB, **Bristow MR**, Hammond EH, Menlove RL, Ensley RD, Ratkovec RM, Renlund DG. Antimurine antibody to OKT3 in cardiac transplantation: Implications for prophylaxis and retreatment of rejection. *Transplant Proceed* 23:1157–1159, 1991.
132. O'Connell JB, Renlund DG, **Bristow MR**, Hammond EH. Detection of allograft endothelial cells of recipient origin following ABO-compatible, nonidentical cardiac transplantation. *Transplantation* 51:438–442, 1991.
133. Hershberger RE, Feldman AM, Anderson FL, Kimball JA, Wynn JB, **Bristow MR**. A M_r 40,000 and M_r 39,000 pertussis toxin substrates are increased in surgically denervated dog ventricular myocardium. *J Cardiovasc Pharm* 17:568–575, 1991.
134. O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt C, Jones KW, Gay WA, Menlove RL, **Bristow MR**. Sensitization to OKT3 monoclonal antibody in heart transplantation: Correlation with early allograft loss. *J Heart Lung Transplant* 10:217–222, 1991.
135. Hammond EH, Ensley RD, Yowell RL, Craven CM, **Bristow MR**, Renlund DG, O'Connell JB. Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection. *Transplant Proceedings* 23:26–30, 1991.

136. Hershberger RE, Feldman AM, **Bristow MR**. A₁ adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. *Circulation* 83:1343–1351, 1991.
137. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D, **Bristow MR**. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. *JACC* 17:1373–1381, 1991.
138. O'Connell JB, Renlund DG, Gilbert EM, **Bristow MR**. Enoximone as a bridge to cardiac transplantation: The Utah experience. *J Heart Lung Transplant* 10:477–481, 1991.
139. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, **Bristow MR**. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. *Circulation* 83:1866–1872, 1991.
140. Feldman AM, Jackson DG, **Bristow MR**, Cates AE, Van Dop C. Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: Discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate. *J Mol Cell Cardiol* 23:439–452, 1991.
141. Movsesian MA, Smith CJ, Krall J, **Bristow MR**, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. *J Clin Invest* 88:15–19, 1991.
142. Lee HR, Hershberger RE, Port JD, Rasmussen R, Renlund DG, O'Connell JB, Gilbert EM, Mealey PC, Volkman K, Menlove R, **Bristow MR**. Low-dose enoximone in subjects awaiting cardiac transplantation: Clinical results and effects on β -adrenergic receptors. *J Thoracic Cardiovasc Surg* 102:246–258, 1991.
143. Richenbacher WE, Karwande SV, Shaddy RE, Renlund DG, **Bristow MR**, O'Connell JB, Gay WA. Cardiac transplantation in a patient with a single ventricle and transposition of the great vessels. *Ann Thorac Surg* 52:871–873, 1991.
144. **Bristow MR**, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in β -adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. *Circulation* 84:1024–1039, 1991.
145. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, **Bristow MR**. β -blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation* 84:2426–2441, 1991.
146. Feldman AM, Ray PE, **Bristow MR**. Expression of α -subunits of G proteins in failing human heart: A reappraisal utilizing quantitative polymerase chain reaction. *J Mol Cell Cardiol* 23:1355–1358, 1991.
147. Gilbert EM, O'Connell JB, **Bristow MR**. Therapy of idiopathic dilated cardiomyopathy with chronic β -adrenergic blockade. *Heart and Vessels Suppl* 6:29–39, 1991.
148. Anderson FL, Port JD, Reid BB, Larrabee P, Hanson G, **Bristow MR**. Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy: Correlation with β -adrenergic downregulation. *Circulation* 85:46–53, 1992.
149. Renlund DG, **Bristow MR**, Olsen SL, O'Connell JB. Current concepts in clinical cardiology: cardiac transplantation. *AHA Council on Clinical Cardiology Newsletter*. American Heart Association, JS Alpert, editor. Winter:8–17, 1991/1992.
150. **Bristow MR**, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. β -adrenergic neuroeffector abnormalities in the failing human heart are produced by local, rather than systemic mechanisms. *J Clin Invest* 89:803–815, 1992.
151. **Bristow MR**, Larrabee P, Müller-Beckmann B, Minobe W, Roden R, Skerl RL, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. *Clin Investig* 70: 105–113, 1992.
152. Price GD, Olsen SL, Taylor DO, O'Connell JB, **Bristow MR**, Renlund DG. Corticosteroid-free maintenance immunosuppression after heart transplantation; feasibility and beneficial effects. *J of Heart & Lung Transplant* 11(2):403–414, 1992.
153. Merigan TC, Renlund DG, Keay S, **Bristow MR**, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, Richenbacher WE, Millar RC, DuMond C, DeAmond B, Sullivan V, Cheney T, Buhles W, Stinson EB. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. *NEJM* 326:1182–1186, 1992.

154. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O'Connell JB, **Bristow MR**, Doty DB, Millar RC, Karwande SV, Jones KW, Gay, Jr., WA, Renlund DG. Vascular rejection and its relationship to allograft coronary artery disease. *J of Heart & Lung Transplant* 11(3):S111-S119, 1992.
155. Port JD, DeBellis CC, Klein J, Peeters GA, Barry WH, **Bristow MR**. Pharmacological characterization of chick and frog beta adrenergic receptors in primary cultures of myocardial cells. *J Pharm Exp Ther* 262(1):217-224, 1992.
156. **Bristow MR**, Feldman AM. Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. *In* Cellular and Molecular Alterations in the Failing Human Heart, G. Hasenfuss, Ch. Holubarsch, H. Just, N.R. Alpert, eds., *Basic Res Cardiol* 87(Suppl 1):15-35, 1992.
157. **Bristow MR**, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Müller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. *J Cardiovasc Pharmacol* 19(Suppl 1): 68-80, 1992.
158. Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, **Bristow MR**. Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. *J Cardiovasc Pharm* 20:800-806, 1992.
159. **Bristow MR**. β -adrenergic receptor abnormalities in heart muscle disease. *Newsletter of the Scientific Council on Cardiomyopathy* No. 6 New Series:1-2, 1992.
160. Marks JD, Karwande SV, Richenbacher WE, Jones KW, Doty DB, Millar RC, O'Connell JB, Renlund DG, **Bristow MR**, Pantalos GM, Gay WA. Perioperative mechanical circulatory support for transplantation. *J Heart Lung Transplant* 11:117-1128, 1992.
161. Ratkovec RM, O'Connell JB, **Bristow MR**, Jones KW, Gay WA, Rasmussen LG, Renlund DG. Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy. *Clin Transplantation* 6 (2):260-264, 1992.
162. Ratkovec R, Hammond EH, O'Connell JB, **Bristow MR**, DeWitt C, Richenbacher W, Millar R, Renlund D. Outcome of cardiac transplant patients with a positive donor specific crossmatch: Preliminary results with plasmapheresis. *Transplantation* 54:651-655, 1992.
163. **Bristow MR**. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. *Am J Cardiol* 71:12C-22C, 1993.
164. Gilbert EM, Olsen SL, Renlund DG, **Bristow MR**. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. *Am J Cardiol* 71:23C-29C, 1993.
165. Feldman AM, **Bristow MR**, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. *N Engl J Med* 329:149-155, 1993.
166. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, **Bristow MR**. Lisinopril lowers cardiac adrenergic drive and increases β -receptor density in the failing human heart. *Circulation* 88:472-480, 1993.
167. Olsen SL, Wagoner LE, Hammond EH, Taylor DO, Yowell RL, Ensley RD, **Bristow MR**, O'Connell JB, Renlund DG. Vascular rejection in cardiac transplantation: Clinical correlation, treatment options, and future considerations. *J Heart Lung Transplant* 12:S135-S142, 1993.
168. Olsen SL, Renlund DG, O'Connell JB, Lassetter JE, Eastburn TE, Hammond EN, **Bristow MR**. Trimethoprim sulfamethoxazole prevents pneumocystis carinii pneumonia in cardiac transplant recipients. *Transplantation* 56:359-362, 1993.
169. Baldwin JC, Anderson JL, Boucek MM, **Bristow MR**, Jennings B, Ritsch Jr. ME, Sliverman NA. Heart Transplantation Task Force 2: Donor Guidelines. *JACC* 22:1-64, 1993.
170. **Bristow MR**. Changes in myocardial and vascular receptors in heart failure. *JACC* 22(Suppl A): 61-71, 1993.
171. Deisher TA, Narita H, Zera P, Ginsburg R, **Bristow MR**, Billingham ME, Fowler MB, Hoffman BB. Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. *J Pharmacol & Exp Therap* 266:262-269, 1993.
172. Reynolds MV, **Bristow MR**, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme *DD* genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. *The Lancet* 342:1073-1075, 1993.

173. Ensley RD, **Bristow MR**, Olsen SL, Taylor DO, Hammond EH, O'Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS, Gay WA, Renlund DG. Use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. *Transplantation* 56:75–82, 1993.
174. Farrukh HM, White M, Port JD, Handwerger D, Larrabee P, Klein J, Roden RA, Skerl L, Renlund DG, Feldman AM, **Bristow MR**. Up-regulation of beta₂-adrenergic receptors in previously transplanted, denervated nonfailing human hearts. *JACC* 22:1902–1908, 1993.
175. Waagstein F, **Bristow MR**, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson Å. For the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. *The Lancet* 342:1441–1446, 1993.
176. **Bristow MR**, Minobe W, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced β₁ receptor messenger RNA abundance in the failing human heart. *J Clin Invest* 92:2737–2745, 1993.
177. Hunt SA, Addonizio LJ, Anderson JL, Baldwin JC, Barr ML, Baumgartner WA, Boucek MM, Bourge R, Bowden AB, **Bristow MR**, et al. 24th Bethesda Conference: Cardiac Transplantation, *JACC* 22:1–64, 1993.
178. **Bristow MR**. β receptor down-regulation in the failing human heart. *Citation Classic, Current Contents* 36 (44)8, 1993.
179. Wagoner LE, Olsen SL, Taylor DO, **Bristow MR**, O'Connell JB, Hammond EH, Lappe DL, Renlund DG. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with frequent rejection. *Transplantation* 56:1414–1418, 1993.
180. **Bristow MR**, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orié J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. *Circulation* 89:1632–1642, 1994.
181. **Bristow MR**. Ischemic cardiomyopathy and heart failure. *Coronary Artery Disease* 5:97–100, 1994.
182. **Bristow MR**, Lowes BD. Low-dose inotropic therapy of ambulatory heart failure. *Coronary Artery Disease* 5:112–118, 1994.
183. O'Connell JB, **Bristow MR**. Economic impact of heart failure in the United States: Time for a different approach. *J Heart Lung Transplant* 13:S107–S112, 1994.
184. White M, Roden R, Minobe W, Khan MF, Larrabee P, Wollmering M, Port JD, Anderson F, Campbell D, Feldman AM, **Bristow MR**. Age-related changes in β-adrenergic neuroeffector systems in the human heart. *Circulation* 90:1225–1238, 1994.
185. **Bristow MR**. Is too much or too little hypertrophy of individual cardiac myocytes the problem in the failing heart? *Heart Failure* 10:162–165, 1994.
186. Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, **Bristow MR**. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. *J Cardiac Failure* 1(1):57–62, 1994.
187. Taylor DO, **Bristow MR**, O'Connell JB, Ensley RD, Olsen SL, Hammond EH, Wagoner LE, Renlund DG. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation: decreased sensitization to OKT3. *Transplantation* 58:645–649, 1994.
188. **Bristow MR**. Use of oral enoximone in pharmacologic bridging to cardiac transplantation. *Z Kardiol*. 83 Suppl 2:15-19, 1994.
189. Hunt SA, **Bristow MR**, Kubo SH, O'Connell JB, Young JB. Guidelines for training in adult cardiovascular medicine: Task Force 8: training in heart failure and transplantation. *JACC* 25:29–31, 1995.
190. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, Lowes BD, **Bristow MR**, Perryman MB, Voelkel NF. Importance of angiotensin-converting enzyme in pulmonary hypertension. *Cardiol (Suppl 1)*:9-15, 1995.
191. **Bristow MR**, Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy: A new concept in the treatment of heart failure. *Eur Heart J* 16(Suppl F):20–31, 1995.
192. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, **Bristow MR**. Carvedilol improves left ventricular function and symptoms in heart failure: A double-blind randomized study. *JACC* 25:1225–1231, 1995.

193. Shaddy RE, Olsen SL, **Bristow MR**, Taylor DO, Bullock EA, Tani LY, Renlund DG. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. *Amer Heart J* 129:197–199, 1995.
194. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). *Am J Cardiol* 75:1220–1223, 1995.
195. White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, Hammond E, Abraham WT, Wolfel EE, Lindenfeld J, Fullerton D, **Bristow MR**. Cardiac β -adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: Evidence for catecholamine-mediated myocardial damage. *Circulation* 92:2183–2189, 1995.
196. Williams JF, **Bristow MR**, Fowler MB, Francis GS, Garson A, Gersh BJ, Hammer DF, Hlatky MA, Leier CV, Packer M, Pitt B, Ulliyot DJ, Wexler LF, Winters WL. Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). *J Am Coll Cardiol* 26:1376-1398, 1995, and *Circulation* 92:2764-2784, 1995.
197. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, Renlund D, Mealey P, Abraham WT, **Bristow MR**. Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. *Am J Cardiol* 76:1271–1276, 1995.
198. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaipe RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Reynolds MV, **Bristow MR**, Perryman MB. Angiotensin II formation in the intact human heart: Predominance of the angiotensin-converting enzyme pathway. *J Clin Invest* 96:1490–1496, 1995.
199. Jagers J, Fullerton DA, Campbell DN, Andrea B, Jones SD, Brown JM, Wolfel EE, Lindenfeld J, Grover FL, **Bristow MR**. Cardiac allograft failure: Successful use of biventricular assist device. *Ann Thorac Surg* 60:1409-1411, 1995.
200. Costanzo MR, Augustine S, Bourge R, **Bristow MR**, O'Connell JB, Driscoll D, Rose E. Selection and treatment of candidates for heart transplantation: A Statement for Health Professionals (Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association) *Circulation* 92:3593-3612, 1995.
201. **Bristow MR**, Abraham WT. Anti-adrenergic effects of angiotensin converting enzyme inhibitors. *Eur Heart J* 16:37-41, 1995.
202. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, **Bristow MR**. Pharmacologic and hemodynamic effects of combined β -agonist stimulation and phosphodiesterase inhibition in the failing human heart. *Chest* 108:1524-1532, 1995.
203. Deisher TA, Ginsburg R, Fowler MB, Billingham ME, **Bristow MR**. Spontaneous reversibility of catecholamine-induced cardiotoxicity in rats. *Am J Cardiovasc Pathol* 5:79-88, 1995.
204. Renlund DG, Taylor DO, Ensley RD, O'Connell JB, Gilbert EM, **Bristow MR**, Ma H, Yanowitz FG. Clinical Heart Transplantation: Exercise capacity after heart transplantation: influence of donor and recipient characteristics. *J Heart Lung Transplant* 15:16-24, 1996.
205. Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, **Bristow MR**. Mechanism of action of OPC-8490 in human ventricular myocardium. *Circulation* 93:817-825, 1996.
206. Richardson P, McKenna W, **Bristow MR**, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfás I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. *Circulation* 93:841-842, 1996.
207. Pende A, Mitchusson KD, DeMaria CT, Blaxall BC, Minobe WA, Sherman JS, **Bristow MR**, Brewer G, Port JD. Regulation of the mRNA-binding protein AUF1 by activation of the β -adrenergic receptor signal transduction pathway. *J Biol Chem* 271: (No. 14)8493-8501, 1996.
208. Packer M, **Bristow MR**, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. For the U.S. Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 334:1349-1355, 1996.
209. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher, D, Roden RL, Minobe W, Tremmel KD, **Bristow MR**. Cardiac adrenergic receptor effects of carvedilol. *Eur Heart J* 17(Suppl B): 8-16, 1996.

210. Ma H, Hammond EH, Taylor DO, Yowell RL, **Bristow MR**, O'Connell JB, Renlund DG. Repetitive histologic pattern of vascular cardiac allograft rejection: increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). *Transplantation* 62:205-210, 1996.
211. Eichhorn EJ, **Bristow MR**. Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure. *Circulation* 94:2285-2296, 1996.
212. Quaiife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, **Bristow MR**. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy. *Am J Cardiol* 78:779-784, 1996.
213. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, **Bristow MR**. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. *Circulation* 94:2817-2825, 1996.
214. **Bristow MR**, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. For the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation* 94:2807-2816, 1996.
215. Colucci WS, Packer M, **Bristow MR**, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. *Circulation* 94:2800-2806, 1996.
216. Taylor DO, **Bristow MR**, O'Connell JB, Price GD, Hammond EH, Doty DB, Karwande SV, Gay WA, Jones KW, Lappe', Renlund Dale G. Improved long-term survival after cardiac transplantation predicted by successful early withdrawal from maintenance corticosteroids. *J Heart Lung Transplant* 15:1039-1046, 1996.
217. Cleland GF, **Bristow MR**, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure: Should they be used and how? *European Heart Journal* 17(11):1629-39, 1996.
218. Wagoner LE, Taylor DO, Olsen SL, **Bristow MR**, O'Connell JB, Hammond EH, Lappe DL, Renlund DG. Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review. *Clinical Transplantation* 10(5):437-43, 1996.
219. Cohn JN, **Bristow MR**, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel of Heart Failure Research. *Circulation* 95:766-770, 1997.
220. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeier TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, **Bristow MR**. Selective downregulation of the angiotensin II AT₁-receptor subtype in failing human ventricular myocardium. *Circulation* 95:1193-1200, 1997.
221. **Bristow MR**, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. *Cardiovasc Drugs Ther* 11:291-296, 1997.
222. Eichhorn EJ, **Bristow MR**. Practical guidelines for initiation of β -adrenergic blockade in patients with chronic heart failure. *Am J. Cardiol* 79:794-798, 1997.
223. **Bristow MR**. Mechanism of action of beta-blocking agents in heart failure. *Am J Cardiol* 80 11A):26L-40L, 1997.
224. Cohn JN, Fowler MB, **Bristow MR**, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. *J. Cardiac Failure* 3:173-179, 1997.
225. Lowes BD, Minobe WA, Abraham WT, Rizeq MN, Bohlmeier TJ, Quaiife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, **Bristow MR**. Changes in gene expression in the intact human heart: down-regulation of α -myosin heavy chain in hypertrophied, failing ventricular myocardium. *J Clin Invest* 100:2315-2324, 1997.
226. Nakao K, Minobe WA, Roden RL, **Bristow MR**, Leinwand LA. Myosin heavy chain gene expression in human heart failure. *J Clin Invest* 100:2362-2370, 1997.
227. Quaiife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, **Bristow MR**. Effects of carvedilol on right ventricular function in chronic heart failure. *Am J Cardiol* 81:247-250, 1998.
228. **Bristow MR**, Port JD. β -adrenergic blockade in chronic heart failure. *Scand Cardiovasc J.* 47:45-55, 1998.

229. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Ferguson DA, **Bristow MR**. Combined oral positive inotropic and beta-blocker therapy for the treatment of refractory Class IV heart failure. *J Am Coll Cardiol* 31:1336-40, 1998.
230. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, **Bristow MR**, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with advanced hemodynamically decompensated heart failure. *J Cardiac Failure* 4(1):37-44, 1998.
231. The Metoprolol in Dilated Cardiomyopathy (MDC) Study Group. Three year follow-up of patients randomized in the metoprolol in dilated cardiomyopathy trial. *Lancet* 351:1180-1181, 1998.
232. **Bristow MR**. Carvedilol treatment of chronic heart failure: A new era. *HEART (S2)*;79:S31-S34, 1998.
233. **Bristow MR**, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DMB, Quaife RA. The pressure-overloaded right ventricle in pulmonary hypertension. *Chest* 114:63S-64S, 1998.
234. **Bristow MR**. Why does the myocardium fail? New insights from basic science. *Lancet* 352: (Suppl I): 8-14, 1998.
235. Asano K, Zisman LS, **Bristow MR**. Angiotensin II receptors in the normal and failing heart. *Journal of Heart Failure Reviews* 3:199-298, 1998.
236. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, Bush EW, Bohlmeier T, Perryman MB, **Bristow MR**. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT₁ receptor density in the failing human heart. *Circulation* 98:1735-1741, 1998.
237. Gerdes AM, Onodera T, Tamura T, Said S, Bohlmeier TJ, Abraham WT, **Bristow MR**. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. *Journal of Cardiac Failure* No (4): 342-348, 1998.
238. **Bristow MR**, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third generation β -blocking agents in chronic heart failure. *Clinical Cardiology* V(21) (Suppl I): I-3-I-13, 1998.
239. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Roden RL, **Bristow MR**, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ. Increased protein kinase C activity and expression of Ca²⁺-sensitive isoforms are present in the failing human heart. *Circulation* 99:384-391, 1999.
240. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, **Bristow MR**. Cellular and molecular remodeling in a heart failure model treated with the β -blocker carteolol. *Am J Physiol* 45:H1678-H1690, 1999.
241. Quaife RA, Lynch D, Badesch DB, Voelkel NF, Lowes BD, Robertson AD, **Bristow MR**. Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. *J Cardiac Failure* 5:46-54, 1999.
242. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, **Bristow MR**, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. *Am J Cardiol* 83:1201-1205, 1999.
243. Lindenfeld JA, Lowes BD, **Bristow MR**. Hypotension with dobutamine. Beta-adrenergic antagonist selectivity at low doses of carvedilol. *Ann Pharmacother* 33:1266-1269, 1999.
244. **Bristow MR**. Mechanisms of development of heart failure in the hypertensive patient. *Cardiology* 92:3-6, 1999.
245. Lowes BD, Simon MA, Tsekova TO, **Bristow MR**. Inotropes in the β -blocker era. *Clin Cardiol* 23(Suppl 3):III-11-III-16, 2000.
246. **Bristow MR**. β -adrenergic receptor blockade in chronic heart failure. *Circulation* 101:558-569, 2000
247. Miyata S, Minobe WA, **Bristow MR**, Leinwand LA. Myosin Heavy Chain Isoform Expression in the failing and non-failing human heart. *Circ Res* 86:386-390, 2000.
248. Bisognano JD, Weinberger HD, Bohlmeier TJ, Pende A, Raynolds MV, Sastravaha A, Roden RL, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci WS, **Bristow MR**, Port JD. Myocardial-directed overexpression of the human β_1 -adrenergic receptor in transgenic mice. *J Mol Cell Cardiol* 32:817-830, 2000.
249. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec W, LeJemtel T, Roden R, Schleman MM, Robertson AD, Gorczynski RJ, **Bristow MR**. Low Dose Enoximone Improves Exercise Capacity in Chronic Heart Failure. *J Am Coll Cardiol* 36:501-508, 2000.

250. Noori A, Lindenfeld J, Wolfel E, Ferguson D, **Bristow MR**, Lowes BD. β -Blockade in Adriamycin- Induced Cardiomyopathy. *J Cardiac Failure* 6:115-9, 2000.
251. **Bristow MR**, Feldman AM, Saxon LA. Heart failure management with biventricular pacing: The Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) Trial. *J. Cardiac Failure* 6:276-85, 2000.
252. **Bristow MR**. Mechanistic and Clinical Rationales for Using Beta Blockers in Heart Failure. *J Card Failure* 6(2 Supl 1):8-14, 2000.
253. Braunwald EB, **Bristow MR**. Congestive Heart Failure: Fifty Years of Progress. *Circulation* 102:IV-14-23, 2000.
254. Whittaker LA, Kenny CC, Grover FL, **Bristow MR**, Bisognano JD. Severe tricuspid regurgitation after mediastinal radiation. *Cardiovascular Reviews and Reports* 22:23-25, 2001.
255. Shakar SF, **Bristow MR**. Low-level inotropic stimulation with Type III phosphodiesterase inhibitors in patients with advanced symptomatic heart failure receiving β -blocking Agents. *Current Cardiology Reports* 3:224-231, 2001.
256. Kinugawa K, Minobe WA, Wood WM, Ridgway EC, Baxter JD, Ribeiro RCJ, Tawadrous MF, Lowes BA, Long CS, **Bristow MR**. Signaling pathways responsible for fetal gene induction in the failing human heart – evidence for altered thyroid hormone receptor gene expression. *Circulation* 103:1089-94, 2001.
257. Fowler MB, Aronson K, **Bristow MR**, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Oster G, Packer M, Richner R, Young S, for the Carvedilol Heart Failure Study Group. Influence of carvedilol therapy on the incidence of hospitalization and costs of care in chronic heart failure. *J Am Coll Cardiol* 37:1692-1699, 2001.
258. Asano K, Zisman LS, Yoshikawa T, **Bristow MR**, Port DJ. Bucindolol, a nonselective β_1 - and β_2 -adrenergic receptor antagonist, decreases β -adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. *J Cardiovasc Pharmacol*; 37:678-691, 2001.
259. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, **Bristow MR**, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *New Engl J Med* 344:1358-1365, 2001.
260. BEST Trial Investigators. A trial of the beta-adrenergic blocker bucindolol in patients with advanced heart failure. *New Engl J Med*; 344:1659-1667, 2001.
261. Freeman K, Lerman I, Kranias EG, Bohlmeier T, **Bristow MR**, Lefkowitz RJ, Iaccariono G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. *J Clin Invest* 107:967-974, 2001.
262. Port JD, **Bristow MR**. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. *J Mol Cell Cardiol* 33:887-905, 2001.
263. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, **Bristow MR**. Milrinone vs. dobutamine in heart failure subjects treated chronically with carvedilol. *Int J Cardiol* 81:141-149, 2001.
264. Schleman KA, Robertson AD, Lindenfeld JA, Lowes BD, Wolfel EE, Ferguson D, **Bristow MR**, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: A multivariate retrospective analysis. *J Cardiac Failure* 7:4-12, 2001.
265. Loh E, Elkayam U, Cody R, **Bristow MR**, Jaski J, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerine in patients with advanced heart failure. *J Cardiac Failure* 7:114-121, 2001.
266. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: Is there a need for new guidelines? *J Cardiac Failure* 7 (2 Suppl 1):8-12; 2001.
267. Port JD, **Bristow MR**. Perspective: β -adrenergic receptors, transgenic mice, and pharmacological model systems. *Mol Pharmacol* 60:629-31, 2001.
268. Sinagra G, Di Lenarda A, Brodsky GL, Taylor MR, Muntoni F, Pinamonti B, Carniel E, Driussi M, **Bristow MR**, Mestroni L. Heart Muscle Disease Study Group. Current perspective new insights into the molecular basis of familial dilated cardiomyopathy. *Ital Heart J* 4:280-286, 2001.
269. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, **Bristow MR**, Long CS, Simpson PC. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. *Circ Res* 89:591-8, 2001.

270. Lindenfeld J, Robertson AD, Lowes BD, **Bristow MR**. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. *J Am Coll Cardiol* 38(7):1950-6, 2001.
271. Leier CV, Young JB, Levine TB, Pina I, Armstrong PW, Fowler MB, Warner-Stevenson L, Cohn JN, O'Connell JB, **Bristow MR**, Nicklas JM, Johnstone DE, Howlett J, Ventura HO, Giles TD, Greenberg BH, Chatterjee K, Bourge RC, Yancy CW, Gottlieb SS. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2--the physical examination. *Congest Heart Failure* 7:297-308, 2001.
272. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, **Bristow MR**. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. *New Engl J Med* 346:1357-1365, 2002.
273. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, **Bristow MR**, Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. *J Cardiac Failure* 8:86-92 2002.
274. Leier CV, Silver MA, Rich MW, Eichhorn EJ, Fowler MB, Giles TD, Johnstone DE, Le Jemtel TH, Lachmann JS, Levine TB, Armstrong PW, Dec WG, Jessup M, Howlett J, Hershberger RE, Cohn JN, Adams KF Jr, Colucci WS, Warner-Stevenson L, Hosenpud JD, **Bristow MR**, Pina I, Baughman KL, Binkley PF, Ventura HO, Francis GS, White M, Miller LW, Berry B, Missov E. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment. *Congest Heart Failure* 8:98-124, 2002.
275. Swedberg K, **Bristow MR**, Cohn JN, Dargie H, Wright TJ, for the MOXSE Investigators. Effects of sustained-release moxonidine, and imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. *Circulation* 105:1797-1803, 2002.
276. Asano K, Bohlmeier TJ, Westcott JY, Zisman LS, Kinugawa K, Good M, Minobe WA, Roden RL, Wolfel EE, Lindenfeld J, Port JD, Perryman MB, Cleveland J, Lowes BD, **Bristow MR**. Altered expression of endothelin receptors in failing human left ventricles *J Mol Cell Cardiol* 34:833-846, 2002.
277. Metra M, Nodari S, D'Aloia, Robertson AD, **Bristow MR**, Dei Cas L. Beta-blocker Therapy Influences the Hemodynamic Response to Inotropic Agents in Patients with Heart Failure. A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. *J Am Coll Cardiol* 40:1248-1258, 2002.
278. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Quaife RA, Robertson AD, **Bristow MR**. Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. *Mol Med* 8:750-760, 2002.
279. Taylor RG, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, Di Lendaria A, Bohlmeier TJ, Ferguson DA, Brodsky GL, Boucek MM, Lascor J, Moss AC, Li WLP, Stetler GL, Spritz RA, Muntoni F, **Bristow MR**, Mestroni L. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. *J Am Coll Cardiol* 41:771-780, 2003.
280. Rathore SS, Curtis JP, Wang Y, **Bristow MR**, Krumholz HM. Serum digoxin concentration and the efficacy of digoxin therapy in the treatment of heart failure: an analysis of the Digitalis Investigation Group (DIG) Trial. *JAMA*. 289:871-878, 2003.
281. **Bristow MR**. Anti-adrenergic Therapy of chronic heart failure: Surprises and new opportunities, *Circulation*. 107:1100-1102, 2003.
282. Bohlmeier TJ, Helmke S, Shuping Ge, Lynch J, Brodsky G, Sederberg II JH, Robertson AD, Minobe W, **Bristow MR**, Perryman MB. Hypoplastic left heart syndrome myocytes are differentiated but possess a unique phenotype. *Cardiovasc Pathol*. 12:23-31, 2003
283. Abraham WT, Reynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, **Bristow MR**, Perryman MB. Angiotensin-converting enzyme DD in patients with primary pulmonary hypertension: increased frequency and association with preserved hemodynamics. *J Renin Angiotensin Aldosterone Syst*. 4:27-30, 2003.
284. Zisman LS, Meixell GE, **Bristow MR**, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. *Circulation*. 108:1679-1681, 2003.
285. Lin Q, Speth R, **Bristow MR**, Canver CC, Zisman LS. Increased angiotensin-(1-7) forming activity in failing human heart ventricles: Evidence for a human heart angiotensinase with substrate preference for angiotensin II. *Circulation*. 108:1707-1712, 2003.

286. Bohlmeier T, Ferdensi A, **Bristow MR**, Takahashi S, Zisman LS. Selective activation of N-Acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes. *J Cardiac Fail.* 9:59-68, 2003.
287. Sucharov CS, Mariner P, Long CS, **Bristow MR**, Leinwand L. YY1 is increased in human heart failure and represses the activity of the human α -MyHC promoter. *J Biol Chem.* 278:31233-31239, 2003.
288. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, **Bristow MR**. The effect of diabetes on outcome of advanced heart failure patients in the BEST Trial. *J Am Coll Cardiol.* 42:914-922, 2003.
289. **Bristow MR**. β -Adrenergic Receptors and Phosphodiesterase: Present and future perspectives. *Seminars in Cardiothoracic and Vascular Anesthesia.* 7:19-21, 2003.
290. **Bristow MR**, Feldman AM, Adams KF, Goldstein S. Selective versus nonselective β -Blockade for heart failure therapy – Are There Lessons to Be Learned From the COMET Trial? *J Cardiac Fail.* 9:444-453, 2003.
291. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, **Bristow MR**, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. *J Cardiac Fail.* 10:15-20, 2004.
292. Helmke SM, Yen C, Krzyzstof Cios KJ, Nunley K, **Bristow MR**, Duncan MW, and M. Benjamin Perryman MB. Simultaneous quantification of human cardiac α - and β -myosin heavy chain proteins by MALDI-TOF mass spectrometry. *Anal Chem.* 76:1683-1689, 2004
293. **Bristow MR**, Krause-Steinrauf H, Nuzzo R, Liang Cheng-Seng, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Domanski MJ, Eichhorn EJ, Lavori P, Zelis R. Effect of Baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial (BEST). *Circulation* 110:1437-1442, 2004.
294. **Bristow MR**, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, Devries DW, Feldman AM, for the COMPANION Investigators. Effect of cardiac resynchronization therapy with and without an implantable defibrillator on morbidity and mortality in advanced chronic heart failure: The COMPANION Trial. *New Engl J Med* 350:2140-2150, 2004.
295. Taylor, MRG, **Bristow MR**. The emerging pharmacogenomics of the beta-adrenergic receptors. *Cong Heart Fail.* 10:281-288, 2004
296. Sucharov CS, Helmke SM, Langer SJ, Perryman MB, **Bristow MR**, Leinwand LA. The Ku protein interacts with YY1, is up-regulated in human heart failure and represses α MyHC gene expression. *Mol Cell Biol* 24:8705-8715, 2004.
297. Pittenger B, Gill EA, MD Holcslaw TL, **Bristow MR**. Carvedilol produces dose-related reduction in QT dispersion in patients with mild to moderate heart failure. *Am J Cardiol* 94:1459-1462, 2004.
298. Movsesian MA, **Bristow MR**. Alterations in cAMP-mediated signalling and their role in the pathophysiology of dilated cardiomyopathy. *Curr Top Dev Biol* 68:25-48, 2005
299. Carniel E, Taylor MRG, Sinagra G, Di Lenarda A, Ku L, Fain PR, Boucek M, Cavanaugh J, Miodic S, Slavov D, Graw S, Feiger J, Zhu X, Dao D, Ferguson DA, Leinwand L, **Bristow MR**, Mestroni L, on behalf of the Familial Cardiomyopathy Registry Research Group. Alpha-myosin heavy chain mutations associated with dilated and hypertrophic cardiomyopathy. *Circulation* 112:54-59, 2005.
300. Domanski M, Fleg J, **Bristow MR**, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. *J Cardiac Fail* 11:83-86, 2005.
301. Mann DL, **Bristow MR**. Mechanisms and Models in heart failure: the biomechanical model and beyond. *Circulation* 111: 2837-2849, 2005.
302. Kinugawa K, Jeong MY, **Bristow MR**, Long CS. Thyroid hormone induces cardiac myocyte hypertrophy in a TR α_1 -specific manner that requires TAK1 and p38 MAPK. *Mol Endocrin* 19:1618-1628. Epub 2005.
303. Sam F, Kerstetter DL, Pimental DR, Mulukutl S, Tabae A, **Bristow MR**, Wilson S. Colucci WS, Sawyer DB. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. *J Card Fail* 11:473-480. 2005.
304. Carson P, Anand I, O'Connor CM, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Feldman AM, **Bristow MR**. Mode of Death in Advanced Heart Failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial. *J Am Coll Cardiol* 46:2329-2334. 2005.

305. Feldman AM, de Lissoyoy G, **Bristow MR**, Saxon LA, De Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, MD, Carson P, Boscoe A, Baker T, Matthew R. Gunderman MR. Cost-Effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. *J Am Coll Cardiol* 46:2311-2321. 2005.
306. Feldman DS, FACC; Carnes CA, Abraham WT, **Bristow MR**. Beta-adrenergic receptors; alterations in signal transduction, and pharmacogenomics in heart failure. *Nature Clin Practice Cardiovasc Med* 2(9):475-483, 2005.
307. Taylor MR, Slavov D, Gajewski A, Vlcek S, Ku L, Fain PR, Carniel E, Di Lenarda A, Sinagra G, Boucek MM, L. Graw SL, PhD, Ruegg P, Feiger J, Zhu X, Ferguson DA, **Bristow MR**, Gotzmann J, Foisner R, Mestroni L, and the Familial Cardiomyopathy Registry Research Group. Thymopoietin (Lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. *Hum Mutat* 26:556-574, 2005.
308. Rivera D, **Bristow MR**. Cardiac resynchronization - A heart failure perspective. *Ann Noninv Electrocardiol* 10 (4 Suppl):16-23, 2005.
309. Lowes BD, Shakar S, Gerber M, J Liard J-F, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, David DeMets D, **Bristow MR**. Rationale and design of the Enoximone Clinical Trials Program. *J Cardiac Fail* 11:659-669, 2005.
310. **Bristow MR**, Adams KF Jr., Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. Roundtable Discussion: The COMET Trial. *Cong Heart Fail* 11:39-44, 2005.
311. Bullinga JR, Alharethi R, Schram MS, **Bristow MR**, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic carvedilol therapy in heart failure. *J Card Fail* 11:693-699, 2005.
312. Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, **Bristow MR**, Long C, Schwartz G. The PPAR- α activator, fenofibrate, fails to provide myocardial protection in ischemia and reperfusion in pigs. *Am J Physiol Heart Circ Physiol* Epub Dec 9. 2005.
313. Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, **Bristow MR**. Serial gene expression profiling in the intact human heart. *J Heart Lung Transplant* 25:579-88, 2006.
314. Quaife RA, Chen MY, Lynch D, Badesch DB, Groves BM, Wolfel E, Robertson AD, **Bristow MR**, Voelkel NF. Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress. *Eur J Med Res* 11:214-220, 2006.
315. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, **Bristow MR**. A polymorphism within a highly conserved β_1 -adrenergic receptor motif alters β -blocker response in multiple models and human heart failure. *Proc Natl Acad Sci* 103: 11288-11293, 2006.
316. **Bristow MR**, Taylor MRG. Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure. In: *Heart failure: molecules, mechanisms and therapeutic targets*. Novartis Found Symp 274, in press.
317. Sucharov CC, Mariner PD, Nunley KR, Long CS, Leinwand LA, **Bristow MR**. A β_1 -adrenergic receptor, CaM Kinase II dependent pathway mediates cardiac myocyte fetal gene induction. *Am J Physiol Heart Circ Physiol* Feb 24, 2006 [Epub ahead of print].
318. Sucharov CC, Langer S, **Bristow MR**, Leinwand L. Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CAMKIV/PKD and PP2A. *Am J Physiol Cell Physiol*. 2006 Jul 5; [Epub ahead of print]
319. **Bristow MR**. Cardiac resynchronization therapy and adrenergic mechanisms. *Am J Physiol Heart Circ Physiol* . July 28, 2006 [Epub ahead of print].
320. Calalb MB, McKinsey TA, Newkirk S, Bohlmeier T, Huynh K, PhD, Olson EN, **Bristow MR**. Increased Phosphorylation-dependent Nuclear Export of Class II Histone Deacetylases in Failing Human Heart. *Circulation*, in revision.
321. Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, **Bristow MR**, Olson EN, McKinsey TA. Regulation of cardiomyocyte hypertrophy by a positive feedback loop involving TRPC channels and calcineurin. (submitted).
322. Kinugawa K, Wang W, Jeong MY, **Bristow MR**, Long CS. Trichostatin A blocks the repression of myocyte-specific gene expression associated with pathologic cardiac hypertrophy. (submitted).

323. Asano K, Mazzeo RS, Reeves JT, **Bristow MR**, and Wolfel EE. Effects of 4,300 m altitude sojourn on sarcolemmal β -adrenergic receptors in human vastus lateralis muscle (submitted).

Abstracts

1. **Bristow MR**, Sherrod TR, Green R D: An analysis of β receptor drug interactions in isolated rabbit atrium and aorta. *Fed Proc* 28:481, 1969.
2. **Bristow MR**, Green RD: Analysis of β receptor interactions in the chronotropic and inotropic responses of isolated rabbit atria. *Pharmacologist* 11:242, 1970.
3. **Bristow MR**, Green RD: Interaction of diazoxide with β -adrenergic receptors in isolated rabbit atria. *Fed Proc* 30:623, 1971.
4. Daniels JR, Billingham ME, Gelbart A, **Bristow MR**: Effect of verapamil and propranolol on adriamycin-induced cardiomyopathy in rabbits. *Circulation* 54 (Suppl II):20, 1976.
5. **Bristow MR**, Mason JW, Billingham ME, Daniels JR: Endomyocardial biopsy and systolic time intervals in detection of adriamycin cardiotoxicity. *Circulation* 54 (Suppl II):80, 1976.
6. Billingham ME, **Bristow MR**, Mason JW, Daniels JR: Endomyocardial biopsy evidence of radiation enhancement of adriamycin cardiotoxicity. *Circulation* 54(4)23, 1976.
7. Schwartz HD, **Bristow MR**, Goldman RH: Myocardial contractility as a function of serum ionized calcium *in vivo*. *Clin Res* 24(3):239, 1976.
8. **Bristow MR**, Mason JW, Billingham ME, Daniels JR: Clinical evaluation of adriamycin cardiomyopathy. *Proc AACR/ASCO* 18:334, 1977.
9. **Bristow MR**: The spectrum of anthracycline-associated cardiotoxicity in man. Presented at Symposium on Adriamycin, Bethesda, September, 1977.
10. **Bristow MR**, Scott RH, Billingham ME, Daniels JR: Acute and chronic cardiovascular effects of doxorubicin in the dog. Cardiomyopathy mediated by vasoactive amines? *Circulation* 58 (Suppl II):19, 1978.
11. Mason JW, **Bristow MR**, Billingham ME, Daniels JR: Studies of the identification, characterization and amelioration of the cardiac toxicity of Adriamycin in animals and man. Presented at the XVII^e Congress de la Societe Internationale d'Hematologie, Paris, July, 1978.
12. **Bristow MR**, Billingham ME, Minobe WA, Masek MA, Daniels JR: Histamine and catecholamines mediate chronic cardiac and renal damage associated with Adriamycin administration. *Clin Res*, May, 1979.
13. **Bristow MR**, Billingham ME, Daniels JR: Histamine and catecholamines mediate Adriamycin cardiotoxicity. *Proc AACR/ASCO* 20:118, 1979.
14. **Bristow MR**, Billingham ME, Minobe WA, Masek MA, Daniels JR: Demonstration that Adriamycin cardiotoxicity is mediated by vasoactive amines. *J Mol Cell Cardiol* 11(1):10, 1979.
15. **Bristow MR**, Mason JW, Billingham ME: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. *Circulation* 60 (Suppl II):44, 1979.
16. Bowden RE, **Bristow MR**, Watson D, Gordon J, Sageman WS, Rainey A Jackson G, Jamieson S, Stinson E, Harrison DC: Prostaglandins and histamine in cardiac transplant rejection. *Clin Res* 27:A155, 1979.
17. Ginsburg R, **Bristow MR**, Harrison DC, Stinson EB: Histamine receptors present in human coronary arteries. *Clin Res* 27(2):A155, 1979.
18. **Bristow MR**, Harrison DC, Stinson EB: Histamine receptors present in human coronary arteries. *Circulation* 60(4)101, 1979.
19. **Bristow MR**: Rational system for cardiac monitoring in patients receiving anthracyclines. Proceedings of the 16th annual Meeting, American Society for Clinical Oncology, May 26–27, 1980, page 356.

20. **Bristow MR**, Lopez M, McKillop J: Specificity and sensitivity of radionuclide ejection fractions in doxorubicin cardiomyopathy. *Proc AACR/ASCO* 21:154, 1980.
21. Cubicciotti R, **Bristow MR**, Ginsburg R, Harrison DC, Stinson EB: Histaminergic receptor mechanisms in the human heart: the positive inotropic response and adenylate cyclase stimulation. *Circulation* (2): III-256, 1980.
22. McKillop JH, Lopez M, **Bristow MR**, Goris ML: Noninvasive screening for adriamycin cardiotoxicity. *Clin Res* 28(2):1418, 1980.
23. **Bristow MR**, Ginsburg R, Minobe WA, Sageman WS, Harrison DC. Receptor density differences may account for focal alterations in vascular reactivity. *Circulation* (2)64:IV-288, 1981.
24. **Bristow MR**, Ginsburg R, Sageman WS, Billingham ME, Stinson EB. Analysis of the β -adrenergic receptor pathway in myocardial disease. *Circulation* (2)64:IV-286, 1981.
25. Lurie K, **Bristow MR**, Ginsburg R, Minobe W, Billingham M, Sageman S, Harrison D. Vascular H₁-receptor up-regulation in rabbits fed a high cholesterol diet. *Circulation* (2)64:IV-272, 1981.
26. Clusin WT, **Bristow MR**, Jaillon P, Brett P, Schroeder JS. Diltiazem and reduced serum ionized calcium both retard ventricular fibrillation following coronary ligation. *Clin Res* 29(2):A181, 1981.
27. Ginsburg R, **Bristow MR**, Schroeder JS, Stinson EB, Harrison DC. Selective action of diltiazem in the isolated human heart. *Circulation* 64(4):23, 1981.
28. Ginsburg R, **Bristow MR**, Davis K, Billingham ME, Schroeder JS: Receptor analysis of the human coronary artery normal distribution and effects of atherosclerosis. *Circulation* 64(4):120, 1981
29. Ginsburg R, **Bristow MR**, Gordon J, Vanbreem C, Stinson EB: Pharmacologic action of nitroglycerin on the isolated human coronary artery. *Circulation* 64(4):122, 1981.
30. Ginsburg R, **Bristow MR**, Vanbreem C, Schroeder JS, Stinson EB, Harrison DC: Evidence for multiple calcium entry channels in the human epicardial coronary artery. *Circulation* 64(4):267, 1981.
31. Kantrowitz NE, Minobe WA, **Bristow MR**, Billingham ME. Histamine-mediated myocardial necrosis. *Circulation* 64(4):282, 1981.
32. Lewis SJ, Lurie K, **Bristow MR**, Sageman WS, Ginsburg R: Myocardial β -adrenergic receptor upregulation in rabbits fed a high cholesterol diets. *Circulation* 64(4):207, 1981.
33. **Bristow MR**, Ginsburg R, Minobe WA, Harrison DC, Reitz BA, Stinson EB. β -adrenergic receptor measurements in normal and failing human right and left ventricle. *Circulation* (4)66:II-207, 1982.
34. **Bristow MR**, McAuley BJ, Ginsburg R, Minobe WA, Baisch EM. Does [³H]nitrendipine bind to sarcolemmal slow channels? *Circulation* (4)66:II-95, 1982.
35. **Bristow MR**, Kantrowitz NE, Billingham ME. Prevention of subacute anthracycline cardiotoxicity by cromolyn sodium. *Circulation* (4)66:II-365, 1982.
36. Baisch EM, Ginsburg R, **Bristow MR**, Guardiai V, Wallwork J, Stinson EB, Schroeder JS, Harrison DC. Comparative effects of flunarazine and diltiazem on isolated human and rabbit hearts. *Clin Res* 30(1)A82, 1982.
37. Baisch EM, Ginsburg R, **Bristow MR**, Guardiai V, Wallwork J, Stinson EB, Schroeder JS, Harrison DC. Selective action of diltiazem, flunarazine and nicardipine on isolated human and rabbit hearts. *Clin Res* 30(2):A169, 1982.
38. Lewis SJ, **Bristow MR**, Lurie KG, Minobe WA, Hoffman BB. Uncoupling of myocardial β -adrenergic receptors in cholesterol fed rabbits. *Circulation* 66(4):207, 1982.
39. Lurie K, **Bristow MR**, Sageman S, Burden K, Reitz RA, Harrison DC. Increased β -adrenergic density in cardiac transplants. *Circulation* 66(4):72, 1982.
40. Lurie KG, **Bristow MR**, Masek m, Billingham ME, Lewis SJ, Sageman WS, Harrison DC. 6-OH dopamine-mediated cardiomyopathy. *Circulation* 66(4):13, 1982.
41. **Bristow MR**, Strosberg AM, and Ginsburg R. Forskolin activation of human myocardial adenylate cyclase. *Circulation* 68(4):III-60, 1983.
42. Ginsburg R, Strosberg AM, **Bristow MR**, Montgomery W. Inotropic potential of forskolin in failing human hearts. *Circulation* 68(4):III-373, 1983.
43. Ginsburg R, Zera P, Barbe S, **Bristow MR**, Vanbreem C. Mechanism of action of ergonovine maleate in rabbit and human vascular smooth muscle. *Circulation* 68(4):61, 1983.

44. Gordon EP, **Bristow MR**, Laser JA, Minobe WA, Fowler MB. Correlation between β -adrenergic receptors in human lymphocytes and heart. *Circulation* 68(4):99, 1983.
45. Gordon EP, Savin WM, **Bristow MR**, Haskell WL: Catecholamines and cardiac hypertrophy in exercise training. *Circulation* 68(4):376, 1983.
46. Savin WM, Gordon EP, Haskell WL, **Bristow MR**: β -adrenergic receptor response to exercise training in the presence of β_1 selective and nonselective blockade. *Circulation* 68(4):148, 1983.
47. Ginsburg R, **Bristow MR**, Zera P. β_2 receptors are coupled to muscle contraction in human ventricular myocardium. *Circulation* II-70(2) 267, 1984.
48. **Bristow MR**, Laser JA, Minobe W, Ginsburg R, Fowler MR. Selective down-regulation of β_1 adrenergic receptors in the failing human heart. *Circulation* II-70(2) 268, 1984.
49. Fowler MB, **Bristow MR**, Laser JA, Ginsburg R, Scott LB, Schroeder JS. β -blocker therapy in severe heart failure: Improvement related to β_1 -adrenergic receptor up regulation? *Circulation* II-70(2) 446, 1984.
50. Fowler MB, **Bristow MR**, Hopkins DG, Laser JA, Ginsburg R, Alderman EL, Schroeder JS. Impaired β -adrenergic inotropic response in severe heart failure. *Circulation* II-70(2) 761, 1984.
51. Kantrowitz NE, Ellias AK, **Bristow MR**, Harrison DC. Histamine induced myocardial damage. *Clin Res* 32(2):A177, 1984.
52. Laser JA, **Bristow MR**, Minobe WA, Fowler MB. β -adrenergic receptor binding in human endomyocardial biopsy tissue. *JACC* 3(2):566, 1984.
53. Anderson FL, Kralios AC, **Bristow MR**. Desensitization of VIP receptors mediating a positive inotropic response in canine heart. *Circulation* 72(Supp III):205, 1985.
54. **Bristow MR**, Minobe W, Rasmussen R, Ginsburg R, Fowler M, Larrabee P. Chamber-specific adrenergic abnormalities in isolated right ventricular failure in the human heart. *Circulation* 72(Supp III):731, 1985.
55. Umans V, Ginsburg R, Zera P, **Bristow M**, Fowler M. Efficacy of β_1/β_2 agonists in isolated normal and failing human hearts. *Circulation* 72(Supp III):1313, 1985.
56. Laser J, **Bristow M**, Menlove R, Billingham M, Lund D, Schmid P. Chamber-specific β -adrenergic receptor regulatory abnormalities in pressure overloaded right ventricle in guinea pigs. *Circulation* 72(Supp III):1314, 1985.
57. **Bristow MR**, Minobe W, Rasmussen R. Differential regulation of alpha and beta-adrenergic receptor in the failing human heart. *Circulation* 72(Supp III):1315, 1985.
58. **Bristow MR**, Laser JA, Ginsburg R, Minobe W. β_1 and β_2 receptors are coupled to adenylate cyclase in human ventricular myocardium. *Clin Research* 33(2):171A, 1985.
59. Fowler MB, Laser JA, **Bristow MR**, Minobe WA, Ginsburg R. β -adrenergic receptor density in right ventricular biopsy samples: Correlation with hemodynamic indices. *JACC* 5(2):535, 1985.
60. Hershberger RE, **Bristow MR**. Failing human left ventricular myocardium is supersensitive to vasoactive intestinal peptide. *Clin Res* 34(2):630A, 1986.
61. Gilbert EM, Sorensen S, Laser J, Lappe D, Burke L, Wong W, Curtis J, Jones K, Gay W, **Bristow MR**: Echocardiography as the primary means of screening cardiac transplant donors. *Circ* 74 (Supp II):712, 1986.
62. Heilbrunn SM, Shah P, Valentine HA, Mullin AV, Ginsburg R, Schroeder JS, **Bristow MR**, Fowler MB. Increased β -receptor density and improved hemodynamic response to catecholamine stimulation during chronic metoprolol therapy. *Circ* 74 (Supp II):1235, 1986.
63. Eiswirth CC, Bowden RE, Kazamias T, Fowler M, **Bristow MR**. Treatment of adriamycin cardiomyopathy with metoprolol. *Circ* 74 (Supp II):1236, 1986.
64. Watson FS, O'Connell JB, Amber IJ, Renlund DG, **Bristow MR**. Treatment of cytomegalovirus pneumonia with 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG). *J Heart Transplantation* 5:390, 1986.
65. The UTAH Cardiac Transplant Team. Heart transplantation at the Utah transplantation affiliated hospitals (UTAH): A regional program for the intermountain west. *J Heart Transplantation* 5:367, 1986.
66. Renlund DG, Gilbert EM, Herrick C, O'Connell JB, Gay WA, **Bristow MR**. Age-associated decrease in cardiac allograft rejection. *J Heart Transplant* 5(5):3, 1986.
67. Gilbert EM, Renlund DG, O'Connell JB, Eiswirth CC, Gay WA, **Bristow MR**. Immunosuppressive efficacy of vincristine in heart transplantation. *J Heart Transplant* 5(5):62, 1986.

68. Gilbert EM, Eiswirth CC, Renlund DG, Herrick CM, Gay WA, **Bristow MR**. OKT3 monoclonal antibody for early prophylaxis in cardiac transplantation. *JACC* 9(2):30A, 1987.
69. Hershberger RE, Ginsburg R, Wynn JR, Anderson FL, **Bristow MR**. The vasoactive intestinal peptide receptor is coupled to adenylate cyclase and muscle contraction in human ventricular myocardium. *JACC* 9(2):137A, 1987.
70. Hershberger RE, Anderson FL, **Bristow MR**. Increased VIP receptor affinity in failing human heart. *Clin Res* 35(3):572A, 1987.
71. Gilbert EM, **Bristow MR**, Renlund DG, O'Connell JB, Watson F, Jones KW, Gay WA, Watson F, Jones KW, Gay WA and the UTAH Cardiac Transplant Program. OKT3 monoclonal antibody is superior to antithymocyte globulin for early prophylaxis in cardiac transplantation. *Circulation* 76(Supp IV):1021, 1987.
72. Gilbert EM, Hershberger RE, Watson F, O'Connell JB, Renlund DG, **Bristow MR**. Additivity of the effects of enoximone and dobutamine in the failing human heart. *Circulation* 76(Supp IV):1016, 1987.
73. Gilbert EM, Eiswirth CC, Mealey P, Herrick G, **Bristow MR**. The transplanted human heart exhibits presynaptic, but not postsynaptic adrenergic supersensitivity. *Circulation* 76(Supp IV):239, 1987.
74. Hershberger RE, **Bristow MR**. The A₁ adenosine receptor pathway in failing and nonfailing human heart. *Circulation* 76(Supp IV):1726, 1987.
75. Rasmussen R, Shah P, Larrabee P, Murray J, Ginsburg R, Renlund DG, O'Connell JB, **Bristow MR**. β_1 and β_2 receptor down-regulation associated with β agonist administration in the failing human heart. *Circulation* 76(Supp IV):1221, 1987.
76. Gilbert EM, Anderson JL, Deitchman D, Bartholomew M, Mealey P, Yanowitz FG, **Bristow MR**. Chronic β -blockade with bucindolol improves resting cardiac function in dilated cardiomyopathy. *Circulation* 76(Supp IV):1423, 1987.
77. Rasmussen R, Minobe W, Narita H, Ginsburg R, **Bristow MR**. Are calcium channels altered in the failing human heart? *Circulation* 76(Supp IV):2128, 1987.
78. Hershberger RE, Gilbert EM, Anderson JL, Mealey P, Wynn J, Soltani E, **Bristow MR**, O'Connell JB, Renlund D. Mechanism of Action of Bucindolol in the Failing Human Heart. *JACC* 11(2):143A, 1988.
79. Sandoval A, Gilbert EM, Ginsburg R, Rasmussen R, Minobe W, Larrabee P, **Bristow MR**. Is β_1 receptor down-regulation in the failing human heart the result of exposure to cardiac-derived norepinephrine? *JACC* 11(2):117A, 1988.
80. Port JD, **Bristow MR**. Myocardial β_2 receptor subsensitivity in the failing human heart. *JACC* 11(2):117A, 1988.
81. Hershberger RE, Anderson FL, **Bristow MR**. The vasoactive intestinal peptide receptor in failing and nonfailing human ventricular myocardium: Supersensitivity of failing heart due to increased receptor affinity; diminished maximal inotropic response from decreased receptor density. *JACC* 11(2):143A, 1988.
82. Hegewald MG, O'Connell JB, Renlund DG, Burton NA, Karwande SV, Jones KW, **Bristow MR** and the UTAH Cardiac Transplant Program. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppression prophylaxis in cardiac transplantation. *J Heart Transplant* 7:76(131), 1988.
83. Renlund DG, O'Connell JB, Gilbert EM, Burton NA, Jones KW, Karwande SV, Menlove RL, Gay WA, **Bristow MR** and the UTAH Cardiac Transplant Program. Comparison of OKT3- versus ATG- based early prophylaxis: decreased rejection and corticosteroid use with OKT3. *J Heart Transplant* 7:69(104), 1988.
84. Crandall BG, Renlund DG, O'Connell JB, Burton NA, Jownes KW, Lee HR, Menlove RL, **Bristow MR** and the UTAH Cardiac Transplant Program. Increased cardiac allograft rejection in female cardiac transplant recipients. *J Heart Transplant* 7:70(106), 1988.
85. O'Connell JB, Renlund DG, Gilbert EM, DeWitt CW, Herrick CM, Holland C, Gay WA, **Bristow MR**, and the UTAH Cardiac Transplant Program. Treatment of refractory cardiac allograft rejection with OKT*3 monoclonal antibody in recipients with prior OKT*3 exposure. *J Heart Transplant* 7:74(124), 1988.
86. O'Connell JB, Renlund DG, DeWitt CW, **Bristow MR**, and the UTAH Cardiac Transplant Program. Cardiac transplantation in sensitized recipients without a prospective crossmatch. *J Heart Transplant* 7:74(123), 1988.
87. Hershberger RE, Rasmussen R, **Bristow MR**. M₁ and M₂ muscarinic receptor pathways in failing human ventricular myocardium. *Clin Res* 36:541A, 1988.

88. Shaddy RE, **Bristow MR**. In vitro and in vivo comparative effects of forskolin and isoproterenol in young lambs. *Clin Res* 36:201A, 1988.
89. Port JD, **Bristow MR**. Lack of spare β -adrenergic receptors in the human heart. *FASEB J* 2(4):A602, 1988.
90. Port JD, DeBellis CC, **Bristow MR**. Pharmacologic characterization of cultured chick and frog myocardial β -adrenergic receptors. *The Pharmacologist* A96, 1988.
91. Feldman AM, Cates AE, **Bristow MR**, Van Dop C. Expression of the αG_i gene in the failing heart. *J Mol Cell Cardiol* 20:17, 1988.
92. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, **Bristow MR**. Effect of lisinopril on cardiac adrenergic drive and myocardial β -receptor density in heart failure. *Circulation* 78:2298, 1988.
93. Gilbert EM, Mealey P, Volkman K, Eastburn T, O'Connell JB, Renlund DG, **Bristow MR**. Combination therapy with enoximone and dobutamine is superior to nitroprusside and dobutamine in heart failure. *Circulation* 78:109, 1988.
94. Deisher TA, Billingham M, **Bristow MR**, Ginsburg R, Fowler MB. Evaluation of the protective effect of several beta-adrenoceptor antagonists in epinephrine-induced cardiotoxicity in rats. *Circulation* 78:119, 1988.
95. Port JD, DeBellis CC, Wiederin J, Peeters GA, Hershberger RE, Barry WH, **Bristow MR**. Long-term β -adrenergic receptor desensitization in cultured chick myocardial cells. *FASEB J* 3(4):4756, 1989.
96. Anderson J, Gilbert E, O'Connell J, Renlund D, Yanowitz F, Batholomew M, Murray M, Mealey P, Volkman K, **Bristow MR**. Beneficial effects of long-term beta-blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. *JACC* 12:117A, 1989.
97. Port JD, Hershberger RE, Gilbert EM, **Bristow MR**. β -adrenergic agonists in nonfailing, failing, and transplanted human hearts. *JACC* 13:143A, 1989.
98. Gilbert EM, Larrabee P, Rasmussen R, Volkman K, **Bristow MR**. Hemodynamic correlates of increased cardiac adrenergic drive in the intact failing human heart. *JACC* 13:245A, 1989.
99. Gilbert EM, Volkman K, Mealey PC, **Bristow MR**. Tachyphylaxis associated with dopexamine administration in severe heart failure. *JACC* 13:247A, 1989.
100. Lee HR, O'Connell JB, Renlund DG, Gilbert EM, Mealey PC, Volkman K, Larrabee PA, **Bristow MR**. Use of enoximone in cardiac transplant candidates; effect on β adrenergic receptors. *JACC* 13:248A, 1989.
101. Hershberger RE, Feldman AM, Anderson FL, Kimball JA, Wynn JR, **Bristow MR**. A M_r 40,000 pertussis toxin substrate (G-protein) is increased in denervated dog heart. *Clin Res* 37(2):518A, 1989.
102. Gilbert EM, Mestroni L, Anderson JL, Woodley SL, **Bristow MR**. Can response to β -blocker therapy in idiopathic dilated cardiomyopathy be predicted by baseline parameters? *Circulation* 80(4):II-428, 1989.
103. Sandoval AB, Gilbert EM, Rose CP, **Bristow MR**. Cardiac norepinephrine uptake and release is decreased in dilated cardiomyopathy. *Circulation* 80(4):II-393, 1989.
104. Woodley SL, Gilbert EM, Anderson JL, Deitchman D, Mealey P, O'Connell JB, Renlund DG, **Bristow MR**. Differing effect of chronic β -blockade with bucindolol on cardiac function in patients with idiopathic vs ischemic cardiomyopathy. *Circulation* 80(4):11-118, 1989.
105. Port JD, Larrabee P, Wiederin J, Durham DW, Rasmussen R, **Bristow MR**. Differences in ventricular myocardial β receptor expression in ischemic vs idiopathic dilated cardiomyopathy. *Circulation* 80(4):II-8, 1989.
106. Feldman AM, Jackson DG, **Bristow MR**, Van Dop C. Immunologic quantification of G proteins in failing and non-failing human heart. *Circulation* 80(4):II-293, 1989.
107. Crandall BG, Gilbert EM, Menlove RL, Herrick CM, Holland CS, Hagan MB, Karwande SV, O'Connell JB, Renlund DG, **Bristow MR**. Immunosuppressive efficacy of vincristine in cardiac transplantation: Decreased rejection frequency and increased removal from steroids. *J Heart Transplant* 8:95, 1989.
108. Olsen SL, O'Connell JB, **Bristow MR**, Renlund DG. Methotrexate (MTX) in the treatment of persistent cardiac allograft rejection. *J Heart Transplant* 8:96, 1989.
109. O'Connell JB, Renlund DG, DeWitt CW, Hammond EH, Yowell RL, Craven C, Menlove RL, Jones KW, Gay WA Jr, **Bristow MR**. Sensitization to OKT3: Correlation with early allograft loss. *J Heart Transplant* 8:95, 1989.

110. Lassetter JE, Renlund DG, O'Connell JB, Rollins J, Fairfax W, Smith CB, Watson F, **Bristow MR**. The effect of immunosuppression on the incidence of interstitial pneumonias in cardiac transplant patients. *J Heart Transplant* 8:94, 1989
111. Anderson FL, Port JD, **Bristow MR**, Hershberger RE, Kralios A, Hanson G. Neuropeptide Y in the failing ventricle of patients with idiopathic dilated cardiomyopathy. *JACC* 15:30A, 1990.
112. Woodley SL, O'Connell JB, Renlund DG, Herrick CM, Gay WA, Jones KW, Moore CK, **Bristow MR**. Safety and efficacy of intraoperative vs postoperative administration of OKT3 in orthotopic cardiac transplantation. *JACC* 15:69A, 1990.
113. O'Connell JB, Greenwood JH, **Bristow MR**, Hammond EH, Wittwer CT, Yowell RL, Renlund DG. Sensitization to OKT3: Increased frequency with prolonged administration. *JACC* 15:69A, 1990.
114. Port JD, Skerl L, O'Connell JB, Renlund DG, Larrabee P, **Bristow MR**. Increased expression of β_2 -adrenergic receptors in surgically denervated, previously transplanted human ventricular myocardium. *JACC* 15:84A, 1990.
115. Wiechmann RJ, Eastburn T, Murray J, Port JD, O'Connell JB, Renlund DG, Hershberger RE, **Bristow MR**. Cardiac donor heart dysfunction: evidence for catecholamine-mediated myocardial injury. *JACC* 15:84A, 1990.
116. Hershberger RE, Kimball JA, Minobe W, Rasmussen R, **Bristow MR**. Muscarinic receptor pathways in nonfailing and failing human heart. *JACC* 15:171A, 1990.
117. **Bristow MR**, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Deitchman D. Dose-response of beta blocker therapy in heart failure: a multicenter, randomized trial of bucindolol versus placebo. *Circulation* 82 (4):III-674, 1990.
118. **Bristow MR**, Skerl L, Jackson DG, Larrabee P, Feldman AM. Uncoupling of β -adrenergic receptors and increased Gi in ischemic dilated cardiomyopathy. *Circulation* 82 (4):III-567, 1990.
119. Ratkovec RM, O'Connell JB, Renlund DG, **Bristow MR** and the UTAH Cardiac Transplant Program. Use of plasmapheresis in cardiac transplant recipients with an IgG positive crossmatch. *Circulation* 83 (4):III-713, 1990.
120. Renlund DG, **Bristow MR**, Ratkovec RM, O'Connell JB. Does corticosteroid-free maintenance immunosuppression increase the risk of subsequent allograft rejection? *J Heart Transplant* 9:61, 1990.
121. Renlund DG, O'Connell JB, Ratkovec RM, Jones KW, Gay Jr. WA, Karwande SV, Richenbacher WE, Doty DB, Millar RC, **Bristow MR**. Exclusion of the older heart transplant candidate from consideration: Lack of medical justification. *J Heart Transplant* 9:56, 1990.
122. Hershberger RE, Nimer LR, O'Connell JB, Murray JL, Wong WA, Ratkovec RM, Gay Jr. WA, Jones KW, Doty DB, Karwande SV, Millar RC, Richenbacher WE, **Bristow MR**, Renlund DG. Use of progressively older donor cardiac allografts. *J Heart Transplant* 9:57, 1990.
123. SL Olsen, Eastburn TE, Renlund DG, JB O'Connell, Lassetter JE, **Bristow MR**. Trimethoprim-sulfamethoxazole prevents pneumocystis carinii pneumonia in cardiac transplant recipients. *J Heart Transplant* 9:59, 1990.
124. Woodley SL, O'Connell JB, Renlund DG, Herrick CM, Millar RC, Karwande SV, Doty DB, Gay WA Jr, Jones KW, Moore CK, **Bristow MR**. Intermediate follow-up of intraoperative vs postoperative administration of OKT3 in orthotopic cardiac transplantation. *J Heart Transplant* 9:61, 1990.
125. Moore CK, Renlund DG, Rasmussen LG, Hershberger RE, **Bristow MR**, O'Connell JB. Hypercholesterolemia after heart transplantation: Lack of a dose-related cyclosporine effect. *J Heart Transplant* 9:77, 1990.
126. **Bristow MR**, Skerl L, Larrabee P, Minobe W, Rasmussen R, Ginsburg R. An abnormality in the catalytic subunit of adenylate cyclase characterizes pressure-overloaded, failing human ventricular myocardium. *JACC* 17:100A, 1991.
127. Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, **Bristow MR**. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. *JACC* 17:142A, 1991.
128. Focaccio A, Minobe W, Movsesian MA, Krall J, Peeters G, Eki Y, **Bristow MR**. Evidence for phosphodiesterase inhibitory activity of OPC-8490 in the failing human heart. *JACC* 17:250A, 1991.
129. Focaccio A, Larrabee P, Wollmering MM, **Bristow MR**. Xamoterol has agonist activity in end-stage failing human heart. *JACC* 17:250A, 1991.

130. Minobe W, Larrabee P, **Bristow MR**. Mechanism of action of carvedilol in human ventricular myocardium. *JACC* 17:250A, 1991.
131. Pickrell J, Hammond E, Larrabee P, **Bristow MR**. Comparison of sympathetic innervation of failing and nonfailing human hearts by quantitative evaluation of catecholamine fluorescence. *JACC* 71:220A, 1991.
132. Wiechmann RJ, Wollmering MM, **Bristow MR**. IL-1 inhibits β -adrenergic responsiveness in intact human ventricular myocardium. *JACC* 17:57A, 1991.
133. Wollmering MM, Wiechmann RJ, Port JD, Hershberger RE, Focaccio A, **Bristow MR**. Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium. *JACC* 17:283A, 1991.
134. **Bristow MR**, Durham C, Kline J, Rasmussen R, Port JD, Gesteland RR, Barry WH, Feldman AM. Down-regulation of β -adrenergic receptors and receptor mRNA in heart cells chronically exposed to norepinephrine. *Clin Res* 39:256A, 1991.
135. Movsesian MA, Smith CJ, Krall J, **Bristow MR**, Manganiello VC. Sarcoplasmic reticulum-associated cyclic AMP phosphodiesterase activity in normal and failing human hearts. *Clin Res* 39:159A, 1991.
136. Marks JD, Karwande SV, Richenbacher WE, O'Connell JB, Renlund DG, **Bristow MR**, Pantalos GM, Gay Jr. WA. Perioperative mechanical circulatory support for transplantation. *J Heart Transplantation* 10:160, 1991.
137. Merigan T, Renlund D, Keay S, **Bristow MR**, Starnes V, O'Connell J, Resta S, Dunn D, Gamberg P, Ratovec R, DuMond C, Stinson E. A multicenter, randomized, double-blind, placebo controlled study of CMV prophylaxis with intravenous ganciclovir (DHPG) in cardiac transplantation. *J Heart Transplantation* 10:175, 1991.
138. Ratkovec RM, O'Connell JB, **Bristow MR**, Ensley RD, Karwande SV, Millar RC, Renlund DG. Prevalence of invasive malignancies following OKT3 therapy in cardiac transplantation. *J Heart Transplantation* 10:163, 1991.
139. Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Volkman K, O'Connell JB, Yanowitz FD, **Bristow MR**. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy. *Circulation* 84:II-564, 1991.
140. Gilbert EM, Olsen SL, Mealey P, Volkman K, Larrabee P, **Bristow MR**. Is β -receptor up-regulation necessary for improved LV function in dilated cardiomyopathy? *Circulation* 84:II-469, 1991.
141. Feldman AM, **Bristow MR**, Ray PE. G protein gene expression in human heart by quantitative polymerase chain reaction. *Circulation* 84:II-394, 1991.
142. Ensley RD, Olsen SL, **Bristow MR**, O'Connell JB, Dunn D, Swanson S, Kauffman RS, Renlund DG. RS-61443, a novel immunosuppressant, in cardiac transplantation: a phase I clinical trial. *Circulation* 84:II-487, 1991.
143. White M, Gilbert EM, Yanowitz F, Mealey P, Olsen S, Larrabee P, **Bristow MR**. Relation of β -adrenergic receptor status to peak exercise in idiopathic dilated cardiomyopathy. *Circulation* 84:II-53, 1991.
144. White M, Wollmering M, Handwerger D, Klein J, Larrabee P, **Bristow MR**. Age related changes in β_1 and β_2 adrenergic receptors and adenylate cyclase stimulation in nonfailing and failing human hearts. *JACC* 19(3):194A, 1992.
145. Meixell GE, Wollmering MM, Hershberger RE, **Bristow MR**. M_2 muscarinic receptors are coupled to a positive inotropic response in human ventricular myocardium. *JACC* 19(3):346A, 1992.
146. Olsen SL, Yanowitz FG, Gilbert EM, Mealey PC, Volkman AK, Renlund DG, **Bristow MR**. β -blocker related improvement in submaximal exercise tolerance in heart failure from idiopathic dilated cardiomyopathy (IDC). *JACC* 19(3):146A, 1992.
147. **Bristow MR**, Olsen SL, Gilbert EM, Larrabee PA, Volkman AK, Mealey PC, Ferguson D, White M, Renlund DG, O'Connell JB. β -blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart. *JACC* 19(3):146A, 1992.
148. Gilbert EM, Larrabee PA, Volkman AK, Mealey PC, Renlund DG, Olsen SL, **Bristow MR**. Does dobutamine tolerance result from myocardial β -receptor down-regulation? *JACC* 19(3):253A, 1992.
149. Gilbert EM, Renlund DG, Olsen SL, **Bristow MR**. Use of an inotropic bridge to β -blockade in dilated cardiomyopathy with severe heart failure. *Clin Res* 40(2):259A, 1992.

150. White M, Wollmering M, Roden R, Port JD, Minobe W, Skerl L, Handwerger D, **Bristow MR**. Age-related decrease in β -adrenergic responsiveness is not expressed in previously transplanted, denervated human heart. *Can J Cardiol* 8(Suppl B):96B, 1992.
151. White M, Wollmering M, Roden R, Port JD, Minobe W, Skerl L, Handwerger D, **Bristow MR**. Decreased G protein functional activity and uncoupling of β -adrenergic receptors from mechanical response in the aging human heart. *Can J Cardiol* 8(Suppl B):121B, 1992.
152. Feldman AM, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG., for the OPC-8212 Investigators and Coordinators. Results of a multi-center study of OPC-8212 in chronic congestive heart failure. *Circulation* 86(Suppl I): I-374, 1992.
153. **Bristow MR**, Handwerger D, Klein J, Port JD. Down regulation of cardiac β_1 -adrenergic receptors by "atypical," β -blocking agents. *Circulation* 86(Suppl I): I-646, 1992.
154. Roden RL, **Bristow MR**, Krall J, Movsesian MA. Inotropic action of flosequinan in isolated human heart: evidence for phosphodiesterase inhibition at high concentrations. *Circulation* 86(Suppl I): I-645, 1992.
155. White M, Wollmering M, Roden RL, Port JD, Minobe W, Skerl L, Handwerger DA, **Bristow MR**. Decreased G protein functional activity, decreased agonist affinity and uncoupling of β -adrenergic receptors from mechanical response with aging in the human heart. *Circulation* 86(Suppl I): I-766, 1992.
156. Gilbert EM, Anderson FL, Larrabee PA, Olsen S, Volkman AK, **Bristow MR**. Flosequinan selectively lowers cardiac adrenergic drive in the failing human heart. *Circulation* 86(Suppl I): I-644, 1992.
157. White M, Gilbert EM, Anderson JL, O'Connell JB, Olsen S, Renlund DG, **Bristow MR**. Do β -blocking agents improve left ventricular function in subjects with ischemic dilated cardiomyopathy? *JACC* 21(Suppl A):115A, 1993.
158. **Bristow MR**, Gilbert EM, Olsen S, Larrabee P, Renlund DG, O'Connell JB. Long-term metoprolol therapy increases myocardial β -adrenergic receptor density relative to placebo controls. *JACC* 21(Suppl A):101A, 1993.
159. Abrams J, **Bristow MR**, Chiang Y-K, Dec GW, Dennish GW, Fenney L, Gilbert EM, Hariman RJ, Renlund DG, Routh JD, Ryan M, Steiner C, Strain J, Wolff A, Wunsch C, Yellen L. double-blind evaluation of the safety and efficacy of nicardipine in patients with advanced chronic congestive heart failure. *JACC* 21(Suppl A):377A, 1993.
160. **Bristow MR**, Olsen S, Larrabee P, Gilbert EM. The β -blocking agents metoprolol and carvedilol affect cardiac adrenergic drive differently in subjects with heart failure from idiopathic dilated cardiomyopathy. *JACC* 21(Suppl A):314A, 1993.
161. Roden RL, Mitchusson KD, Skerl L, **Bristow MR**. Inotropic action of OPC 18790 in the isolated failing and nonfailing human heart. *JACC* 21(Suppl A):365A, 1993.
162. **Bristow MR**, Minobe WA, Port JD, Ray PE, Feldman AM. Decreased β_1 -adrenergic receptor mRNA levels correlate with decreased β_1 receptor density in the failing human heart. *JACC* 21(Suppl A):100A, 1993
163. Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Taylor DO, Volkman AK, **Bristow MR**. Carvedilol improves symptoms and left ventricular function in patients with congestive heart failure due to ischemic or idiopathic dilated cardiomyopathy. *JACC* 21(Suppl A):114A, 1993.
164. Gilbert EM, Yanowitz FG, Anderson JL, O'Connell JB, **Bristow MR**. Effect of long term β -blockade with metoprolol on exercise tolerance in patients with idiopathic dilated cardiomyopathy. *JACC* 21(Suppl A):115A, 1993.
165. Reynolds MV, **Bristow MR**, Bush E, Zisman LS, Taft CS, Perryman MB. Angiotensin converting enzyme D/D genotype is increased in ischemic and idiopathic dilated cardiomyopathy. *Cardiovasc Drugs & Therap* 7(Suppl. 2):426, 1993.
166. Quaife RA, Gilbert EM, Olsen SL, Christian PE, Datz FL, **Bristow MR**. Carvedilol improves left ventricular systolic but not diastolic function in heart failure. *Circulation* 88(4):I-104, 1993.
167. Feldman AM, Pepine CJ, **Bristow MR**, Hendrix GH, Powers ER, Bertolet B, Baughman KL, Young N, Coward TD, White BG, for the Vesnarinone Investigators. Incidence of vesnarinone induced neutropenia: The U.S. experience. *Circulation* 88(4):I-301, 1993.
168. Carson PE, Colucci WS, Deedwania PC, Uretsky BF, **Bristow MR**, Feldman AM, Coward TD, for Vesnarinone Investigators. Lack of proarrhythmia or arrhythmia reduction by vesnarinone in advanced heart failure. *Circulation* 88(4):I-602, 1993.

169. Cody RJ, Leier CV, **Bristow MR**, Fifer MA, Binkley PF, Haas GJ, Starling RC, Abraham WT, Lowes BD, Dec GW, Semigran MJ, Cowart TD. OPC-18790 produces titratable hemodynamic benefit in hospitalized patients with severe congestive heart failure. *Circulation* 88(4):I-300, 1993.
170. Deisher TA, Billingham M, **Bristow MR**, Ginsburg R, Fowler MB. Evaluation of the protective effects of several beta-adrenoceptor antagonists in epinephrine-induced cardiotoxicity in rats. *Circulation* 78 (4): II-30, 1993.
171. **Bristow MR**, Minobe WA, Reynolds MV, Roden RL, Port JD, Feldman AM. Age-related decreases in β_1 receptor mRNA abundance in human heart. *J Am Coll Cardiol* February 17A. 1994
172. Abraham WT, Lowes BD, Rose CP, Larrabee P, **Bristow MR**. Angiotensin II selectively increases cardiac adrenergic activity in patients with heart failure. *J Am Coll Cardiol* February:215A. 1994
173. Abraham WT, Reynolds MV, **Bristow MR**, Badesch DB, Groves BM, Lowes BD, Wynne KM, Voelkel NF, Perryman MB. Increased frequency of the angiotensin converting enzyme D/D genotype in patients with severe pulmonary hypertension. *J Am Coll Cardiol* February 1994:177A.
174. Gilbert EM, Renlund DG, Olsen SL, Reynolds L, Mealey PC, Larrabee P, **Bristow MR**. Hemodynamic and neuroendocrine effects of chronic vesnarinone administration in heart failure: A placebo-controlled trial. *J Am Coll Cardiol* February:173A. 1994.
175. Lindenfeld J, Gilbert EM, Abraham WT, Olsen S, Wolfel E, **Bristow MR**. Does gender affect the response to medical therapy in heart failure? *Clin Res* 42:323A, 1994.
176. Lindenfeld J, White M, Roden RA, Port JD, **Bristow MR**. Gender-related differences in age-associated down-regulation of human ventricular myocardial β -adrenergic receptors. *Clin Res* 42:333A, 1994.
177. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, **Bristow MR**. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β adrenergic receptor blocking agents. *Circulation* 90(4):I-543, 1994.
178. Hajjar RJ, Khan F, Liao R, Fuleihan F, **Bristow MR**, Gwathmey JK. Acute effects of β -blockade and β -agonism in an animal model of dilated cardiomyopathy treated with chronic β -blockade: correlation with β_1 and β_2 receptor density. *Circulation* 90(4):I-212, 1994
179. Khan MF, Lindenfeld J, Chavez D, **Bristow MR**. Appearance of β -receptor antibodies in heart failure patients with myocardial dysfunction and no histologic evidence of rejection. *Circulation* 90(4):I-420, 1994
180. Zisman L, Bush EW, Taft CS, **Bristow MR**, Perryman MB, Reynolds MV. Increase in angiotensin converting enzyme gene expression and activity in the failing human ventricle. *Circulation* 90(4):I-578, 1994.
181. Reynolds MV, Bush EW, Taft CS, Roden RA, **Bristow MR**. Altered gene expression of several rate limiting enzymes in fatty acid oxidation and glycolysis in the failing human heart. *Circulation* 90(4):I-209, 1994.
182. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaipe RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Reynolds MV, **Bristow MR**, Perryman, MB. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. *J Invest Med* 43(Suppl 2):239A, 1995.
183. Lowes BD, Abraham WT, Minobe W, Feldman AM, **Bristow MR**. Assessment of gene expression in endomyocardial biopsy specimens from failing and nonfailing human hearts. *J Invest Med* 43(Suppl 2):316A, 1995.
184. Ensley RD, O'Connell JB, Renlund DG, Olsen SL, Taylor DO, Gilbert EM, **Bristow MR**, Yanowitz FG. Corticosteroid withdrawal is associated with improved exercise capacity following cardiac transplantation. *Transplant Proc*, 1995.
185. Asano K, Minobe W, Mitchusson KD, Dutcher D, Roden RL, Port JD, **Bristow MR**. Selective down-regulation of angiotensin II AT₁ receptors in failing human heart: relationship to β_1 -receptor down-regulation. *J Am Coll Cardiol* February: 291A. 1995.
186. Meixell GE, Wangsgaard WP, Blumenthal DK, **Bristow MR**. Differential regulation of phosphorylase kinase in failing human left ventricular myocardium. *J Am Coll Cardiol* February: 91A 1995.
187. Minobe W, Lowes BD, Abraham WT, Feldman AM, **Bristow MR**. *In vivo* measurement of myocardial gene expression in the human heart. *J Am Coll Cardiol* February: 277A. 1995.
188. Abraham WT, Reynolds MV, Badesch DB, Lowes BD, Groves BM, Wynne KM, Voelkel NF, Perryman MB, **Bristow MR**. The angiotensin converting enzyme DD genotype is associated with preserved right

- ventricular function in patients with severe primary pulmonary hypertension. *J Am Coll Cardiol* February: 27A 1995.
189. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Lowes BD, Roden RL, Quaipe RA, Groves BM, Perryman MB, **Bristow MR**. Angiotensin II formation in the intact human heart: predominance of the angiotensin converting enzyme pathway. *J Am Coll Cardiol* February:234A. 1995.
 190. Abraham WT, Lowes BD, Ferguson DA, Wolfel EE, Lindenfeld J, Schrier RW, **Bristow MR**. Systemic hemodynamic and renal excretory effects of a continuous 4-hour infusion of human brain natriuretic peptide in patients with heart failure. *J Am Coll Cardiol* February 1995:236A.
 191. Khan F, Hajjar RJ, Liao R, Fuleihan F, **Bristow MR**, Gwathmey JK. Myocardial adenylyl cyclase activity in an animal model of dilated cardiomyopathy treated chronically with the non-selective β -blocker carvedilol. *J Am Coll Cardiol* February 1995:293A.
 192. Port JD, Mitchusson KD, Pende A, Minobe W, Brewer G, **Bristow MR**. Regulation of p37AUF1, an mRNA binding protein, in human ventricular myocardium. *FASEB J* 9:A1277, 1995.
 193. Lowes BD, Abraham WT, Minobe W, Feldman AM, **Bristow MR**. Assessment of gene expression in endomyocardial biopsy specimens from failing and nonfailing human hearts. *J Invest Med* 43:316A, 1995.
 194. **Bristow MR**, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersol H, for the MOCHA Investigators. Multicenter oral carvedilol heart failure assessment (MOCHA): A six-month dose-response evaluation in class II-IV patients. *Circulation* 92(Suppl I):I-142, 1995.
 195. Pickrell JW, Abraham WT, Port JD, Roden RL, **Bristow MR**, Hammond EH. Evidence for decreased adrenergic nerve density in the failing human heart. *Circulation* 92(Suppl I):I-191, 1995.
 196. Mitchusson KD, Roden RL, Abraham WT, **Bristow MR**, Port JD. Regulation of the neuronal norepinephrine transporter by its endogenous ligand. *Circulation* 92(Suppl I):I-568, 1995.
 197. Packer M, **Bristow MR**, Cohn JN, Colucci WS, Fowler MB, Gilbert EM. Effect of carvedilol on the survival of patients with chronic heart failure. *Circulation* 92(Suppl I):I-142, 1995.
 198. Colucci WS, Packer M, **Bristow MR**, Cohn JN, Fowler MB, Gilbert EM, Krueger SK, Adams KF, Hershberger R, Uretsky BF. Carvedilol inhibits clinical progression in patients with mild heart failure. *Circulation* 92(Suppl I):I-395, 1995.
 199. Roden RL, Minobe WA, Dutcher DL, Tremmel KD, Port, JD, **Bristow MR**. Differential regulation of β 1 and β 2 adrenergic receptors and mRNA by non-selective β agonist exposure in preparations of isolated human heart. *J Am Coll Cardiol* February 1996: 288A.
 200. Colucci WS, **Bristow MR**, Packer M, Shusterman NH, Fowler MB, Gilbert EM, Young S. Maintenance of long-term survival benefit in CHF patients treated with carvedilol. *J Am Coll Cardio* February 1996, 169A.
 201. Packer M, **Bristow MR**, Shusterman, Colucci WS, Fowler MB, Gilbert EM, Young S. Maintenance of long-term survival benefit in CHF patients treated with carvedilol. *Circulation* 94 (Suppl) I-664, 1996.
 202. **Bristow MR**, Gilbert EM, Abraham WT, Adams KF, Fowler M, Hershberger RE, Kubo SH, Narahara KA, Robertson AD, Krueger SK. Effect of carvedilol on LV function and mortality in diabetic vs non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. *European Heart J* 17:78, 1996.
 203. **Bristow MR**, Colucci WS, Fowler M, Gilbert EM, Lukas MA, Young S, Hershberger RE, Krueger SK, Meilman, Liang. Effect of carvedilol on survival and hospitalization in patients with ischemic or nonischemic cardiomyopathy. *J Am Coll Cardiol* February 1996: 169A.
 204. Abraham WT, Lowes BD, Roden RL, Lindenfeld J, Wolfel EE, Zisman LS, Kaufman D, Rose CP, **Bristow MR**. Cardiac tracer norepinephrine kinetics in orthotopic heart transplant recipients: evidence for late re-innervation. *European Heart J* 17:64, 1996.
 205. Packer M, **Bristow MR**, Cohn JN, Colucci WS, Fowler MB, Gilbert EM. Favorable effect of carvedilol on morbidity and mortality of patients with chronic heart failure. *European Heart J* 17:78, 1996.
 206. Colucci WS, Packer M, **Bristow MR**, Cohn JN, Fowler MB, Gilbert EM, Krueger SK, Adams KF, Hershberger R, Shusterman N. Carvedilol inhibits clinical progression in patients with mild heart failure. *European Heart J* 17:78, 1996.
 207. **Bristow MR**, Abraham WT, Gilbert EM, Yoshikowa T, Port JD. Relationship between carvedilol stereoisomer plasma concentrations and β -receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial. *European Heart J* 17:135, 1996.

208. Raynolds MV, Roden RL, Blain-Nelson P, **Bristow MR**, Perryman MB. Association of genetic variants in the angiotensin II type 1 receptor and angiotensinogen with end-stage heart muscle disease. *J Am Coll Cardiol*. February 1996 27A.
209. Lowes BD, Abraham, WT, Dutcher DL, Roden RL, Crisman, TS, Minobe W, Port JD, Larrabee P, Gilbert EM, **Bristow MR**. Comparative anti-adrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled-trial. *Circulation* 94 (Suppl) I-664, 1996.
210. Quaife RA, Lynch D, Groves B, Voelkel, Herrold EM, Wynne K, Bristow MR, Badesch DB. Elevated right ventricular circumferential wall stress inversely correlates with right ventricular systolic function in primary pulmonary hypertension. *Circulation* 94(Suppl):I-647, 1996.
211. Lowes BD, Gill EA, Rodriguez-Larrain, J, Abraham WT, Gilbert EM, **Bristow MR**. Carvedilol is associated with a reversal of remodeling in chronic heart failure. *Circulation* 94 (Suppl) I-407, 1996.
212. **Bristow MR**, Colucci WS, Fowler MB, Gilbert EM, Lukas MA, Young ST, Hershberger RE, Adams S, Melman H, Liang C-S. Effect of carvedilol on survival and hospitalization in patients with ischemic or non-ischemic cardiomyopathy. *Circulation* 94 (Suppl) I-338, 1996.
213. **Bristow MR**, Gilbert, EM, Abraham WT, Adams, KF, Fowler MB, Hershberger R, Kubo, SH, Narahara KA, Robertson, AD, Krueger S. Effect of Carvedilol on LV Function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. *Circulation* 94 (Suppl) I-664, 1996.
214. Abraham WT, Lowes BD, Ferguson DA, Wolfel EE, Robertson, AD, Lindenfeld J, **Bristow MR**, Schrier RW. Distal tubular sodium delivery is a determinant of the natriuretic response to hBNP in heart failure patients. *Circulation* 94 (Suppl) I-94, 1996.
215. Colucci WS, Packer M, **Bristow MR**, Fowler MB, Gilbert EM, Cohn JN, Young ST, Shusterman NH, for the Carvedilol Heart Failure Study Group. Carvedilol reduces clinical progression in patients with moderate-severe heart failure. *J Am Coll Cardiol* February 1997: 63A.
216. Packer M, Colucci WS, Cohn JN, **Bristow MR**, Fowler MB, Gilbert EM, Hu JZ, Shusterman NH for the US Carvedilol Heart Failure Study Group. Relationship between long-term changes in left ventricular function and clinical outcome in patients with chronic heart failure treated with carvedilol. *J Am Coll Cardiol* February 1997: 64A.
217. Abraham WT, Oren RM, Crisman TS, Robertson AD, Shakar S, Lowes BD, Panther L, Kelley P, Pies CJ, **Bristow MR**, Schrier RW. Effects of an oral, non-peptide, selective V₂ receptor vasopressin antagonist in patients with chronic heart failure. *J Am Coll Cardiol* February 1997: 169A.
218. Zisman LS, Dutcher DL, Jenkin M, Bush EW, Bohlmeier TJ, **Bristow MR**, Perryman MB. Cardiac tissue angiotensin converting enzyme (ACE) binding sites are increased in human heart failure. *J Am Coll Cardiol* February 1997: 230A.
219. RD Bies, Maeda M, Holder E, Valent S, Roden R, Abraham WT, **Bristow MR**. Microtubule assembly affects β -adrenergic mediated contractility in human ischemic dilated cardiomyopathy. *J Am Coll Cardiol* February 1997: 230A.
220. Zisman LS, Asano K, Dutcher DL, Perryman MB, **Bristow MR**. Differential regulation of cardiac angiotensin converting enzyme (ACE) binding sites and AT₁ receptor density in primary pulmonary hypertension (PPH). *J Am Coll Cardiol* 29(Suppl A):244A, 1997.
221. Fowler MB, Colucci WS, **Bristow MR**, Packer M, Gilbert EM, Cohn JN, Wu B, Hu JZ, Lukas MA, Kubo S, Hershberger R, Gottlieb S, Pina I for the US Carvedilol Heart Failure Study Group. Tolerability of carvedilol initiation in heart failure patients. *J Am Coll Cardiol* February 1997: 285A.
222. Nakao K, Minobe WA, Roden RL, **Bristow MR**, Leinwand LA. Naturally-occurring silent sequence polymorphisms in the human β myosin heavy chain gene. *J Am Coll Cardiol* February 1997: 345A.
223. Lowes BD, Minobe WA, Abraham WT, Roden RL, Port JD, Gilbert EM, Larrabee P, **Bristow MR**. Downregulation of α - and upregulation of β -myosin heavy chain in intact, failing human ventricles. *J Am Coll Cardiol* February 1997: 422A.
224. Bisognano JD, Pende A, Tremmel KD, Bohlmeier TJ, Knudson O, **Bristow MR**, Port, JD. Preliminary characterization of a transgenic mouse overexpressing the human β_1 -adrenergic receptor. *J. Invest. Med.* 1997;45:3, 210A.

225. **Bristow MR**, Gilbert EM, Lowes BD, Minobe W, Shakar S, Quaife RA, Abraham WT. Changes in myocardial gene expression associated with β -blocker-related improvement in ventricular systolic function. *Circulation* 96 (Suppl) I-92, 1997.
226. Vikstrom KL, Weinberger HD, Hoover E, Port JD, Knudson OA, Valdes-Cruz L, **Bristow MR**, Leinwand LA. Alterations in β -adrenergic receptor density precede the development of LV systolic dysfunction in a transgenic mouse model of cardiomyopathy. *Circulation* 96 (Suppl) I-570, 1997.
227. Abraham WT, Lowes BD, Roden RL, Gilbert EM, Havranek EP, White M, Zisman LS, Rose CP, **Bristow MR**. Mechanism of increased cardiac adrenergic activity in heart failure: evidence for decreased cardiac neuronal norepinephrine re-uptake. *Circulation* 96 (Suppl) I-92, 1997.
228. Raynolds MV, Bohlmeyer TJ, Blain-Nelson P, **Bristow MR**. Inverse association between expression of p21^{cip1} and proliferating cell nuclear antigen in human ventricular myocardium. *Circulation* 96(Suppl) I-570, 1997.
229. Nakao K, Minobe W, Roden RL, **Bristow MR**, Leinwand LA. Myosin heavy chain gene expression in human heart failure. *Circulation* 96 (Suppl) I-117, 1997.
230. **Bristow MR**, Gilbert EM, Packer M, Colucci WS, Lukas MA, Court M, Fowler MB, Cohn JN. Effects of carvedilol in elderly patients with chronic heart failure. *Circulation* 96 (Suppl) 577, 1997.
231. Gill EA, Gilbert EM, Lowes BD, Abraham WT, **Bristow MR**, Reiter MJ. Carvedilol reduces QT dispersion in patients with congestive heart failure. *Circulation* 96 (Suppl) I-577, 1997.
232. Zisman LS, Roden RL, Perryman MB, **Bristow MR**. Renin binding protein gene expression is increased in the failing human heart. *J. Invest. Med.* 44 (Suppl A): 305A, 1997.
233. Port JD, Weinberger HD, Bisognano JD, Knudson OA, Bohlmeyer TJ, Pende A, **Bristow MR**. Echocardiographic and histopathological characterization of young and old transgenic mice over-expressing the human β_1 -adrenergic receptor. *J Am Coll Cardiol* 31 (2) (Suppl A): 177A, 1998.
234. Tsvetkova TO, Farber DJ, Abraham WT, Kelly P, Eichhorn E, Gilbert EM, Robertson AD, Lindenfeld J, Wolfel EE, Zisman L, **Bristow MR**. Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol. *J Cardiac Failure* 4(3):Suppl 1 36, 1998.
235. Bowling N, Estridge T, Fouts R, Song G, Roden R, **Bristow MR**, Walsh R, Sabbah H, Sanddusky G, Mizrahi J, Gromo G, Vlahos C. Increased protein kinase C expression in failing human heart. *J Am Coll Cardiol* 31 (2) (Suppl A): 203A, 1998.
236. Lowes BD, Abraham WT, Minobe WA, Gilbert EM, Roden RL, **Bristow MR**. Regulation of α - and β -myosin heavy chain gene expression in the intact, failing human heart: reciprocal regulation and possible signaling by wall stress. *Circulation* 98 (Suppl) I-625, 1998.
237. Lowes BD, Abraham WT, Minobe WA, Gilbert EM, Roden RL, **Bristow MR**. Dynamic Changes in the expression of contractility-regulating genes in the failing human heart associated with improvement or deterioration in ventricular systolic function. *Circulation* 98 (Suppl) I-361, 1998.
238. Wichman SE, Minobe WA, Roden RL, Port JD, Asano K, **Bristow MR**. Differential regulation of β_1 - and β_2 -adrenergic receptor proteins and β_1 -adrenergic receptor protein and mRNA expression in response to β -agonist exposure in isolated human heart preparations. *Circulation* 98 (Suppl) I-491, 1998.
239. Abraham WT, Tsvetkova T, Lowes BD, Ferguson DA, Gilbert EM, **Bristow MR**. Carvedilol improves renal hemodynamics in patients with chronic heart failure. *Circulation* 98 (Suppl) I-378, 1998.
240. Asano K, Zisman LS, Bohlmeyer TJ, Perryman MB, **Bristow MR**. Upregulated endothelin ET_A and downregulate ET_B receptors in the failing human heart. *Circulation* 98 (Suppl) I-420, 1998.
241. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Roden RL, **Bristow MR**. β -blocker-related improvement in ventricular function is associated with increased gene expression of SR Ca²⁺ ATPase. *J Am Coll Cardiol* 33 (2) (Suppl A): 216A, 1999.
242. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Roden RL, **Bristow MR**. Effects of changes in cardiac adrenergic activity on gene expression in the intact failing human heart. *J Am Coll Cardiol* 33 (2) (Suppl A): 210A, 1999.
243. Wolfel EE, Lowes BD, Abraham WT, Roden RL, Robertson AD, Lindenfeld J, Gilbert EM, **Bristow MR**. Withdrawl of chronic β -blockade in heart failure patients does not influence exercise hemodynamics. *J Am Coll Cardiol* 33 (2) (Suppl A): 200A, 1999.

244. Kinugawa K, Minobe WA, Wood W, Ridgway CE, Lowes BD, Baxter JD, Riberio RCJ, Long CS, **Bristow MR**. Signaling pathways responsible for fetal gene expression in the failing human heart: Evidence for altered thyroid hormone receptor gene expression. *Circulation* 100:I-507, 1999.
245. Communal C, Colucci WS, Sawyer DB, Port JD, Wichman SE, **Bristow MR**, Singh K. Differential modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases in failing human myocardium. *Circulation* 100:I-199, 1999.
246. Zisman LS, Ferdensi A, Speth RC, Perryman MB, **Bristow MR**. Selective increase in angiotensin1-7 forming activity in failing human heart ventricles. *Circulation* 100:I-625, 1999.
247. Wolfel EE, Lowes BD, Shakar S, Noori A, Abraham WT, Roden RL, Lindenfeld J, Gilbert EM, **Bristow MR**. Lack of effect of acute withdrawal of either carvedilol or metoprolol therapy on peak and submaximal capacity in nonischemic cardiomyopathy patients with chronic heart failure. *Circulation* 100:I-202, 1999.
248. Lindenfeld J, Lowes BD, Robertson AD, **Bristow MR**, MOCHA Investigators. Aspirin may blunt the beneficial effect of β -blockers on ejection fraction in patients with heart failure. *Circulation* 100:I-784, 1999.
249. Sederberg J, Wichman SE, Lindenfeld J, Wolfel E, Lowes B, Shakar S, Roden R, **Bristow MR**. Bucindolol has no sympathomimetic activity in nonfailing ventricular preparations. *J Am Coll Cardiol*; 35(2) 207A:1137-147, 2000.
250. Lowes BD, Lindenfeld JA, Gilbert EM, Zelis R, Domanski M, Eichhorn EJ, Krause-Steinrauf H, **Bristow MR**. Differential Effects of β -blocking Agents on Adrenergic Activity. *J Cardiac Failure* 2000 (in press).
251. Eichhorn EJ, Domanski M, Adams K, **Bristow MR**, Carson P, Yancy CW, Krause-Steinrauf H. Hemodynamic, Myocardial Functional and Neurohormonal Responses to β -blockade in Black vs. Non-Black Patients in BEST. *Circulation* 102:II-778, 2000.
252. Eichhorn EJ, Domanski M, Adams K, Anderson J, **Bristow MR**, Carson P, Yancy CW, Krause-Steinrauf H. Effect of β -blockade on mortality in African-Americans: The β -blocker Evaluation of Survival Trial *Circulation* 102:II-778, 2000.
253. Kinugawa K, Brown DR, Takahashi T, **Bristow MR**, Long CS. Signaling Pathways Related to p38 β are Responsible for IL-1 β -Induced Hypertrophy in Rat Cardiac Myocytes. *Circulation* 102:II-289, 2000.
254. Kinugawa K, Ribeiro RCJ, Baxter JD, Long CS, **Bristow MR**. Differential Regulation of Thyroid Hormone Receptor Isoforms in Pathological and Physiological Hypertrophy in Rat Hearts. *Circulation* 102:II-72, 2000.
255. Gupta M, Paul Ingram P, **Bristow MR**, Jeevanandam V. Cloning and Characterization of a Repressor Factor that is Involved in Down-Regulation of the α -Myosin Heavy Chain (MHC) Gene Expression During Heart Failure. *Circulation* 102:II-626, 2000.
256. Lowes BD, Gilbert EM, Lindenfeld JA, Zelis R, Domanski MJ, Eichhorn EJ, Krause-Steinrauf H, **Bristow MR**. Differential Effects of β -Blocking Agents on Adrenergic Activity. *Circulation* 102:II-628, 2000.
257. Perryman BM, Port JD, Roden RR, Sederberg II JH, **Bristow MR**. A Comparison of Gene Expression in Failing and Non Failing Human Left Ventricular Tissue. *Circulation* 102:II-449, 2000.
258. Flora S, Kerstetter Jr DL, Pimental DR, Mulukutla S, Tabae A, Ngo K, Pligavko CA, **Bristow MR**, Colucci WS, Sawyer DB. Decreased Activity of Manganese Superoxide Dismutase (MnSOD) in Failing Human Myocardium. *Circulation* 102:II-84, 2000.
259. Sucharov CC, **Bristow MR**, Leinwand LA. Transcription Factors Binding to the α MyHC Promoter in Normal and Failing Human Hearts. *AHA Scientific Sessions Circulation* 102:II-143, 2000.
260. Simon MA, Wolfel EE, Lowes BD, **Bristow MR**, Shakar SF. Peak VO₂ Does Not Predict Survival in Heart Failure Patients Treated Chronically with β -Blockers. *J Am Coll Cardiology* 37:188A, 2001.
261. **Bristow MR**, Zelis R, Nuzzo R, Lindenfeld J, Lowes BD, Domanski MJ, Eichhorn EJ, Krause-Steinrauf HJ. Baseline and Three Month Change in Systemic Venous Norepinephrine as Predictors of Clinical Outcomes in the BEST Trial. *J Am Coll Cardiology* 37:281A, 2001.
262. Lowes BD, Minobe WA, Perryman MB, **Bristow MR**. Expression Profiling in the Intact Failing Human Heart. *J Cardiac Failure* 7, Suppl 2: 38, 2001.
263. Kinugawa K, Wang WZ, **Bristow MR**, Long CS. Inhibition of histone deacetylase reverses repression of myocyte-specific gene expression associated with cardiac hypertrophy. *Circulation* 104: II-172, 2001.

264. Linseman JV, Lowes BD, Minobe WA, Lindenfeld JA, Shakar S, Wolfel EW, Robertson AD, Cantu M, Gilbert EM, **Bristow MR**. Marked Impairment of Exercise Tolerance in Subjects with Heart Failure Treated with β -Blocking Agents: Prevalence and Mechanisms. *Circulation* 104:II-553, 2001.
265. Wolfel EW, Lowes BD, Minobe WA, Lindenfeld JA, Shakar S, Robertson AD, Gilbert EM, **Bristow MR**. Molecular and Physiologic Determinants of Improvement in Functional Capacity in Subjects Treated with β -Adrenergic Blocking Agents. *Circulation* 104II-342, 2001.
266. Lowes BD, Wolfel GW, Minobe WA, Lindenfeld JA, Robertson AD, Gilbert EM, **Bristow MR**. Evidence for ongoing β -Adrenergic Signaling of Gene Expression and Heart Rate in CHF Subjects Treated with β -blocking Agents. *Circulation* 104:II-436, 2001.
267. **Bristow M**, Krause-Steinrauf H, Abraham W, Liang C-S, Hattler B, Kruger S, Lindenfeld J, Lowes BD, Olson L, Thaneemit S, Zelis R. Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST. *Circulation* 104:II-755, 2001.
268. Domanski MJ, Krause-Steinrauf MS, Deedwania MD, Ghali J, Gilbert E, Katz R, Lindenfeld J, Lowes B, Martin W, McGrew F, **Bristow MR**. The effect of bucindolol in diabetic and non-diabetic patients with heart failure. *Circulation* 104:II-754, 2001.
269. Tsvetkova TO, Lowes BD, Robertson AD, Shakar SF, Lindenfeld J, **Bristow MR**, Wolfel EE. Ventilatory Response to Exercise in Heart Failure Patients Treated with Beta-Blockers is a Better Predictor of Survival Than Peak Oxygen Consumption. *J Am Coll Cardiology* 39: 147A, 2002.
270. Wolfel EE, Tsvetkova TO, Lowes BD, Lindenfeld J, Shakar SF, Abraham WT, Robertson AD, Gilbert EM, **Bristow MR**. Improved Ventilatory Response at peak Exercise Despite No Change in Peak Oxygen Consumption with Chronic Beta-Blockade in Heart Failure Patients. *J Am Coll Cardiology* 39: 183A, 2002.
271. Zolty R, Passarino G, Taylor MR A, Moss A, Mestroni L and **Bristow MR**. Molecular epidemiology of cardiac actin gene mutations in dilated cardiomyopathy. *J Am Coll Cardiology* 39: 178A, 2002.
272. Lowes BD, Minobe WA, Good M, Meola S, Hunter L, Leach S, Port JD, Perryman MB and **Bristow MR**. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered expression with improvement in dilated cardiomyopathy. *J Cardiac Failure* 8: S13, 2002.
273. Lindenfeld J, Krause-Steinrauf H, Zelis R, Domanski MS, Eichhorn EJ, Lowes BD and **Bristow MR**. The BEST Investigators. Diabetes mellitus is associated with less systemic adrenergic activation in patients with severe, chronic and congestive heart failure. *J Cardiac Failure* 8: S18, 2002.
274. Lowes BD, Minobe WA, Hunter L, Leach S, Port JD, Linseman JV, Perryman, MB and **Bristow MR**. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: characterization of a human model for molecular discovery. *J Cardiac Failure* 8: S35, 2002.
275. Kinugawa K, Wang W, Jeong MY, **Bristow MR**, Long CS. Inhibition of histone deacetylases reverses repression of myocyte-specific gene expression associated with cardiac hypertrophy. *J Cardiac Failure* 8:S224, 2002.
276. Lowes BD, Minobe WA, Good M, Meola S, Hunter L, Leach S, Port JD, Perryman MB, **Bristow MR**. Expression profiling with dynamic modulation of phenotype in human dilated cardiomyopathy: functional categories of genes exhibiting altered expression with improvement in phenotype. *Circulation* 106:II-384, 2002.
277. Calalb M, McKinsey TA, Olson E, **Bristow MR**. Histone deacetylase iv redistributes from the nuclear to cytosolic fractions in the failing human heart, in conjunction with an increase in hdac kinase activity. *Circulation* 106:II-220, 2002.
278. **Bristow MR**, Saxon LA, Boehmer J, Krueger S, McGrew F, Botteron G, Wagoner L, Kass K, Mann D, DeMarco T, Singh S, Carson P, DiCarlo L, Goldstein S, DeMets D, White BG, DeVires DW, Feldman AM. Cardiac resynchronization therapy reduces hospitalizations, and cardiac resynchronization therapy + an implantable defibrillator reduces mortality in chronic heart failure: Results of the COMPANION Trial. 52nd Annual Scientific Session. Presented in Late Breaking Trials, ACC 2003 .
279. Eichhorn EJ, Krause-Steinrauf H, **Bristow MR**, Boehmer J, Cintron G, Hager D, Lejemtel T, Ramanathan KB, Udelson J, Zile M, Adams Jr. K. for the BEST Study Group. Improvement in left ventricular ejection fraction predicts an improved outcome in patients receiving beta-blockade with bucindolol: The BEST Trial. *Circulation* 108:IV-668, 2003.

280. Carson P, Anand I, O'Connor CM, Lindenfeld Jsteinberg J, Ghali J, Jaski B, Lwin A, Feldman AM, **Bristow MR**. Relation of cardiac device therapy to mode of death in advanced heart failure: The COMPANION Trial *Circulation* 108:IV-628, 2003
281. DeMarco T, Boehmer JP, Higginbotham MB, Krueger SK, Lowes B, Fenster PE, Kennett JD, Wagoner LE, Ghali J, Kirlin P, Saxon L, Feldmand AM, **Bristow MR**. Cardiac resynchronization therapy improves functional status and quality of life in heart failure: Results from the COMPANION Trial exercise sub-study. *Circulation* 108:IV-628, 2003.
282. Carniel G, Sinagra G, DiLenarda A, Taylor MR, Ku P, **Bristow MR**, Mestroni L. Alpha-myosin heavy chain mutations associated with dilated and hypertrophic cardiomyopathy. *Eur Heart J*, in press.
283. Sucharov K, Nunley KR, **Bristow MR**. Repression of alpha myosin heavy chain gene expression and promoter activity by the β -agonist isoproterenol-role for Ca^{2+} /calmodulin protein kinase and ERK1/2 pathway. *J Cardiac Failure* 10 (4):S60, 2004.
284. Sucharov CC, Helmke S, Langer S, Perryman B, **Bristow MR**. Leinwand LA. The Ku protein complex interacts with YY1, is up-regulated in human heart failure and represses alpha myosin heavy chain gene expression and promoter activity. *J Cardiac Failure* 10 (4):S17, 2004.
285. Sucharov CC, **Bristow MR**. Phosphatase 2A represses the human alpha myosin heavy chain promoter activity. *J Cardiac Failure* 10 (4):S58, 2004.
286. Feldman AM, Oren RM, Abraham WT, Zisman LS, Shakar SF, Kao A, Mathier M, McGrew FA, Gilbert EM, Leier CV, Carson PE, Lowes BD, Boehmer JP, Krueger SK, Robertson AD, Liard J-F, Gerber MJ, **Bristow MR**. Oral Enoximone in Intravenous Inotrope-Dependent Subjects (EMOTE) – A Phase III, randomized, double-blind, placebo-controlled parallel study of oral enoximone in intravenous inotrope-dependent subjects, Presented in Late Breaking Trials HFSA, Toronto, 2004
287. Liggett SB, M.D., Mialet-Perez J, Thaneemit-Chen S, Wagoner LE, Domanski MJ, M.D., William T. Abraham WT, Anderson JL, Carlquist JF, Ph.D., Krause-Steinrauf H, Lazzeroni LC, Lavori PW, **Bristow MR**. β_1 -adrenergic receptor polymorphisms predict the clinical response to bucindolol in heart failure. Presented in Late Breaking Trials HFSA, Toronto, 2004.
288. Ku L, Taylor M, Dao D, Slavor D, Zhu X, Graw, S, Carniel E, MD, **Bristow MR**, Towbin J, MD, Mestroni L. Danon disease explains the phenotype in a family originally reported as XLCM. *Circulation* 110:III-52, 2004.
289. Tsvetkova TO, Robinson P, Nunley KR, Calalb M, Sucharov CC, **Bristow MR**. PPAR alpha regulatory pathway is activated in patients with severe idiopathic dilated cardiomyopathy. *Circulation* 110:III-24, 2004.
290. Saxon LA, **Bristow MR**, MD, DeMarco T, Krueger SK for the COMPANION Investigators. Procedural outcomes and device performance In The COMPANION Trial of resynchronization yherapy For heart failure. *Circulation* 110:III-43, 2004.
291. Feldman AM, de Lissovoy G, **Bristow MR**, Saxon LA, De Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, MD, Carson P, Boscoe A, Baker T, Matthew R. Gunderman MR. Cost-effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. *J Am Coll Cardiol* 45:60A, 2005
292. Sumner AD, Boehmer J, Saxon LA, Feldman AM, **Bristow MR**. Statin use is associated with a marked Improvement in Survival in an Advanced Heart Failure Population from the COMPANION Trial. *J Am Coll Cardiol* 45:183A, 2005
293. **Bristow MR**, Sucharov C. YY1 protects against pathologic cardiac hypertrophy through a mechanism that involves HDAC5 interaction: Evidence of CaMKII inhibition of YY1HDAC5 interaction *Circ Res* 97:E8, 2005.
294. Dockstader K, **Bristow MR**, Sucharov C. $\beta(1)$ -adrenergic stimulation results in ERK1/2 activation that is prohypertrophic and dependent on camkii and calcineurin *Circ Res* 97:E9, 2005.
295. Sucharov C, **Bristow MR**. TRPC channels and $\beta(1)$ -adrenergic-mediated activation of the fetal gene program *Circ Res* 97:E9, 2005.
296. Robinson PF, Tsvetkova TO, Nunley K, **Bristow MR**, et al. The peroxisomal proliferator-activated receptor-alpha regulatory pathway is activated in patients with severe idiopathic dilated cardiomyopathy. *J Invest Med* 53:S95, 2005.
297. **Bristow MR**, Saxon LA, DeMarco T, Boehmer J, Galle E, Yong P, Ecklund F, Feldman A. What does an

- ICD add to CRT in advanced heart failure patients? An analysis of major clinical endpoints in the CRT vs. CRT-D Groups in the COMPANION Trial. *Circulation* 112:II-673, 2005.
298. Lindenfeld J, Feldman A, Saxon L, Boehmer J, Carson P, Ghali J, Steinberg J, DeMarco T, David Mann D, Yong P, Galle E, Ecklund F, **Bristow MR**. Cardiac resynchronization therapy with and without a defibrillator improves time to death and hospitalization in NYHA Class IV Heart Failure Patients. *Circulation* 112:II-673, 2005.
 299. **Bristow MR**, Saxon L, Boehmer J, DeMarco T, MD, Carson P, MD, Singh S, MD, Yong P, Galle E, MS, Ecklund F, Feldman A. Baseline factors that predict clinical response with cardiac resynchronization therapy: The COMPANION experience. *Circulation* 112:II-673, 2005.
 300. **Bristow MR**, Yong P, Saxon LA, Jaski B, Boehmer J, Galle E, Ecklund F, Feldman A. Do multiple comorbidities diminish the ability of CRT to reduce mortality and hospitalization? *Circulation* 112:II-673, 2005.
 301. **Bristow MR**, Robertson AD, Lavori P, Thaneemit-Chen S, Small KM, Liggett SB. α_{2C} -Adrenergic receptor 322-325 DEL polymorphism enhanced the sympatholytic effect of bucindolol, and adversely affected clinical outcomes in the BEST Trial. *Circulation* 112:II-351, 2005.
 302. Xu J, Lu L, Greyson C, Rizeq M, Nunley K, **Bristow MR**, Long CS, Schwartz GG. The PPAR- α activator, fenofibrate, fails to provide myocardial protection in ischemia-reperfusion in pigs. *J Am Coll Cardiol* 47:210A, 2006.
 303. Tate CW, Robertson AD, **Bristow MR**, Lowes BD. Evaluation of the Patient Global Assessment Questionnaire as a health status measure for heart failure. *J Am Coll Cardiol* 47:260A, 2006.
 304. Greene S, Nunley K, Weber S, Minobe W, **Bristow MR**. ET_A vs. ET_B Receptor Selectivity of Endothelin-1 Receptor Antagonists. *J Am Coll Cardiol* 47:307A, 2006.
 305. Hambleton R, Krall J, **Bristow MR**, Movsesian MA. cAMP-inhibited cGMP hydrolytic activity in human myocardium. poster presented at June, 2006 Gordon Research Conference on role of phosphodiesterases in intracellular signaling.
 306. Nelson B, Morrison J, Nelson P, Port JD, Robertson AD, **Bristow MR**. Beta-blocking agents have codon 389 Arg/Gly genotype specific effects in isolated human heart preparations. AHA Scientific Sessions 2006, submitted.
 307. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Wolfel EE, Brieke A, Robertson AD, **Bristow MR**. In chronic heart failure, chronic renal failure may increase mortality through sympathetic activation. AHA Scientific Sessions 2006, submitted.
 308. Lowes BD, Zolty R, Abraham WT, Robertson AD, Taylor MRG, Liggett SB, **Bristow MR**. Pharmacogenetic therapeutic enhancement of a prespecified composite morbidity-mortality measurement in BEST. AHA Scientific Sessions 2006, submitted.
 309. Sucharov CC, Nelson BC, Morrison J, Nunley KR, Dockstader K, **Bristow MR**. Gene Expression Changes in Isolated Human Ventricular Preparations Treated with the β -Adrenergic Receptor Agonist Isoproterenol. AHA Scientific Sessions 2006, submitted.
 310. Lowes BD, Gottlieb S, Robertson AD, O'Connor C, Port JD, Thaneemit-Chen S, Liggett S, **Bristow MR**. Differential Effects of β -1 Polymorphisms on Mortality, Hospitalizations, and Myocardial Infarctions with Bucindolol Therapy. AHA Scientific Sessions 2006, submitted.
 311. Lindenfeld J, Zolty R, Robertson AD, Lowes BD, Wolfel EE, Brieke A, **Bristow MR**. Increasing Age Decreases the Risk of Sudden Death Compared to Progressive Heart Failure in Patient with Advance Heart Failure. AHA Scientific Sessions 2006, submitted.

Q. Named Lectures given in past 5 years

Available on request